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Doxorubicin (DOX) is a highly potent chemotherapy drug that impacts the entire body 
rather than a targeted treatment area. While DOX treatment assists in the disruption and 
prevention of certain types of cancer growth, it damages many physiological processes in 
the body that were functioning normally and otherwise healthy prior to its administration. 
Damage induced by DOX on organ functioning can lead to other malignancies in the 
body, such as cachexia, cardiotoxicity, and myotoxicity, among others. Skeletal muscle 
relies on myogenic regulatory factors (MRFs), transcription factors expressed by satellite 
cells, for positive regulation of phases of muscle development and response to damage. In 
skeletal muscle, DOX administration has caused decreased MRF levels as well as 
increased myostatin and ubiquitin ligase expression, which are negative regulators of 
muscle mass. Previous findings have reported altered regulatory protein expression and 
shifts in muscle fiber characteristics of the diaphragm (DIA), as well as decline in patient 
respiratory function, following DOX treatment. Creatine monohydrate (Cr) 
supplementation prior to DOX administration has protected skeletal muscle against 
DOX-induced dysfunction, damage, and decline in MRF expression. However, the 
effects of DOX treatment in combination with Cr supplementation on the expression of 





have yet to be investigated. PURPOSE: To investigate the effects of in vivo DOX 
administration, following the completion of two Cr supplementation protocols, on the 
expression of negative regulators of skeletal muscle mass, myostatin and MuRF-1, in the 
DIA tissue of rats sacrificed one- and three-days post-injection (N=115). METHODS: 
Male Sprague-Dawley rats were fed a diet supplemented with a standard Cr dosage of 2% 
for four weeks (CrS), a Cr loading dosage of 4% for one week and 2% for three weeks 
(CrL), or a standard control (CON) diet for four weeks. Based on random assignment, 
animals received an intraperitoneal injection of DOX (15 mg/kg) or saline (SAL) of the 
same volume and underwent anesthesia one- or three-days post-injection. Following DIA 
removal, Western blotting was used to quantify the protein expression of myostatin and 
MuRF-1. RESULTS: In the DIA, there was no significant diet effect, drug effect, or 
interaction at the one-day timepoint relating to myostatin expression (p = 0.255, p = 
0.412, p = 0.770, respectively). There was also no diet effect, drug effect, or interaction 
pertaining to myostatin expression in the DIA at the three-day timepoint. (p = 0.710, p = 
0.935, p = 0.566, respectively). In the DIA, there was no significant diet effect, drug 
effect, or interaction at the one-day timepoint pertaining to the expression of MuRF-1 (p 
= 0.772, p = 0.248, p = 0.137, respectively). There also was no diet effect, drug effect, or 
interaction relating to MuRF-1 expression in the DIA at the three-day timepoint (p = 
0.826, p = 0.931, p = 0.941, respectively). CONCLUSION: There were no significant 
diet effects, drug effects, or interactions at either timepoint among myostatin and MuRF-
1 protein expression in the DIA as determined by two-way ANOVA (p > 0.05). These 





protein expression may contribute to the decline in respiratory function commonly 
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 In 2018, there were nearly two million new cases of cancer in North America 
alone (American Cancer Society: Global Cancer Facts & Figures 4th Edition, 2018), and 
it is anticipated that over half a million individuals in the United States will die of cancer 
in 2019 (American Cancer Society: Cancer Facts & Figures 2019, 2019). The cancer 
death rate in North America has steadily declined for almost 30 years due to greater 
understanding of cancer mechanisms, improved screening techniques, and increased 
mindfulness of cancer-causing materials and products. 
 Chemotherapy is a commonly utilized method of cancer treatment that affects 
several tissues in the body rather than a localized area. Anthracyclines are a class of drugs 
often used in chemotherapy due to their high success rates in the treatment of a majority 
of cancers (Weiss, 1992). Doxorubicin (DOX), an anti-tumor chemotherapy antibiotic 
belonging to the anthracycline drug class, was first administered to patients in Milan, 
Italy, in 1968 (Bonadonna, Monfardini, de Lena, & Fossati-Bellani, 1969). However, 
DOX was not approved by the Food and Drug Administration for use in the United States 
until 1974 (Cassinelli, 2016). 
 A key limitation of DOX administration is the harm it inflicts on organs and 
tissues in the body that were not intended treatment targets. This may cause other damage 






fatigue, and muscle dysfunction. The severity of DOX-induced damage can be predicted 
based on the total administered dose (Thorn et al., 2011), which indicates that the 
prescribed dosage should be sensibly considered in each case (Carvalho et al., 2009). 
 Treatment with DOX has led to feelings of whole-body and skeletal muscle 
fatigue, as well as muscle atrophy, weakness, and dysfunction. At least seven out of every 
ten individuals with cancer have reported symptoms of fatigue (Miller, Maguire, and 
Kearney, 2007). While there are several proposed mediators of skeletal muscle 
dysfunction following DOX treatment, an increased production of reactive oxygen 
species (ROS) is of particular interest. If antioxidant protections are weakened as a result 
of cancer treatment, for example, an overabundance of ROS may be created and cause 
oxidative stress. Furthermore, Gilliam et al. (2012) determined that mitochondrial ROS 
aided DOX in the initiation of skeletal muscle degradation. Although the exact 
mechanisms that lead to muscle damage remain unclear, several studies have investigated 
the effects of DOX administration on components of cardiac, EDL, and SOL muscle 
functioning.  
It has been observed that DOX exerts its effects in dose-, time-, and tissue-
dependent manners. van Norren et al. (2009) reported that incubation of the extensor 
digitorum longus (EDL) muscle in DOX for two hours led to a decline in ex vivo 
maximal force, as well as decreased contraction and relaxation velocity in mice. 
Similarly, Hydock, Lien, Jensen, Schneider, and Hayward (2011) observed that maximal 
twitch force, rate of force production, and rate of force decline were significantly 
decreased five days following administration of a 15 mg/kg dose of DOX. Fatigue rate 






and 15 mg/kg, but was significantly hindered by all three doses in the soleus (SOL). 
These findings suggest that skeletal muscle function in rats is impaired based on the dose 
of DOX administered.  
Additionally, Hydock et al. (2011) explored the effects of DOX treatment on 
myotoxicity in rats and compared the severity of the damage to that of cardiotoxicity. 
Proper functioning of the heart was diminished in a dose-dependent manner and declined 
to the same degree as that of SOL muscle. Therefore, Hydock et al. (2011) were the first 
to report that cardiotoxicity induced by DOX treatment, as well as direct effects of DOX 
on skeletal muscle, contributed to the decline of skeletal muscle function in rats. 
Moreover, Gilliam, Moylan, Callahan, Sumandea, & Reid (2011) found that DOX 
administration led to a decline in contractile force and reduced cross-sectional area of 
muscle fibers in the DIA muscle of rats. Based on these observations, Gilliam, Moylan, 
Callahan, et al. (2011) were the first to report evidence that DOX treatment can lead to 
respiratory dysfunction.  
A time-dependent decline in both cardiac and skeletal muscle function in rats was 
observed by Hayward et al. (2013) five days following a 15 mg/kg dose of DOX. 
Accumulation of DOX was greatest in cardiac muscle, although all muscular tissues 
demonstrated comparable dysfunction severity. Similarly, Yamada, Sugiyama, Kosaka, 
Hayakawa, and Ozawa (1995), injected rats with a total cumulative dose of 15 mg/kg of 
DOX, partially to investigate DOX accumulation in the heart, liver, and diaphragm (DIA) 
tissue. Yamada et al. (1995) concluded that DOX accumulated in the DIA at a greater 
rate 6 and 24 hours following the last DOX injection in comparison to in the heart and 






of tissue, which may explain variances in DOX-induced damage. Specific characteristics 
of the muscle tissue, such as the type of fiber composition, may also influence the 
severity of DOX-induced muscle dysfunction (Hydock et al., 2011).  
In order for muscular contraction to take place, energy must be obtained from 
either adenosine triphosphate (ATP) or phosphocreatine (PCr) (Banerjee et al., 2010). 
The phosphorylated form of creatine, PCr, is synthesized in a reaction catalyzed by the 
enzyme creatine kinase. Creatine is a substance that is naturally formed in the body, but 
its skeletal muscle stores are most effectively increased from oral consumption (Riesberg, 
Weed, McDonald, Eckerson, & Drescher, 2016). The use of creatine as an ergogenic aid 
gained popularity following its reported success from athletes in improving performance 
during the 1992 Summer Olympics (Close, Hamilton, Philp, Burke, & Morton, 2016). 
Dietary creatine supplementation also became more common in the early 1990s in 
response to Harris, Söderlund, and Hultman (1992) whose findings supported the 
testimonies of the Olympic athletes. 
In addition to enhancing athletic performance, creatine supplementation has 
lessened the severity of muscle-wasting disease symptoms, diminished negative effects of 
corticosteroid and chemotherapy treatment on skeletal muscle function, as well as 
modified regulatory protein expression in favor of protection against muscle atrophy. 
Four months of creatine supplementation in boys with Duchenne muscular dystrophy 
(DMD) improved body composition and grip strength of the dominant hand (Tarnopolsky 
et al., 2004). Menezes, Sobreira, Neder, Rodrigues-Júnior, and Martinez (2007) 
demonstrated that creatine supplementation lessened corticosteroid-induced respiratory 






treatment in the SOL and EDL muscles of rats prior to DOX incubation protected against 
DOX-induced force decline in the SOL muscle and dysfunction of both the EDL and 
SOL muscles (Bredahl and Hydock, 2017). Following hypoxia-induced damage in the 
DIA of spiny mice, Cannata et al. (2010) observed doubled concentrations of myostatin 
and muscle RING-finger protein-1 (MuRF-1) mRNA. Maternal creatine supplementation 
reduced the regulatory protein mRNA elevations, which indicated that creatine loading 
prior to birth may have protected the DIA against hypoxia-induced impairments.  
In summary, it is well-established that inhibited muscle growth and increased 
muscle atrophy are present in a variety of tissues as a result of DOX administration. 
Specifically, these unfavorable outcomes may be accompanied by muscular dysfunction 
and fatigue in skeletal muscle. The DIA, the primary inspiratory muscle, is not spared 
from the negative consequences of DOX on skeletal muscle. This observation pertaining 
to the impact of DOX on the DIA may be of particular importance, because dyspnea is a 
widely reported side effect of chemotherapy treatment. Harmful outcomes of DOX 
administration on protein composition and functioning of skeletal muscle, including that 
of the DIA, have been alleviated in past research as a result of supplementation with 
creatine. Overall, this research may provide a greater understanding of mechanisms 
pertaining to DIA myotoxicity, based on myostatin and MuRF-1 protein expression, 
following DOX administration and pretreatment with creatine monohydrate (Cr) in rats. 
Due to the involvement of the DIA muscle in respiration, these findings may also provide 








 Purpose Statement 
 
 The primary purpose of this study was to investigate the effects of in vivo DOX 
administration, following the completion of two dietary Cr supplementation protocols, on 
the expression of myostatin and MuRF-1 in the DIA tissue of rats sacrificed at one- and 
three-day time points after DOX injection.  
Research Hypotheses 
H1 DOX administration at a dose of 15 mg/kg will increase myostatin and 
MuRF-1 protein expression in the DIA tissue of rats.  
 
H2 Both Cr supplementation protocols will attenuate DOX effects on 
myostatin and MuRF-1 expression in the DIA tissue of rats at both time 
points.   
 
H3 The Cr loading protocol, consisting of 4% Cr supplementation for one 
week, followed by 2% Cr supplementation for three weeks, will attenuate 
the effects of DOX on myostatin and MuRF-1 protein expression in the 











CHAPTER II   
REVIEW OF LITERATURE 
Cancer 
According to the American Cancer Society, there were approximately 17 million 
new cases of cancer worldwide in 2018, with more than 1.9 million of those cases in 
North America alone (American Cancer Society: Global Cancer Facts & Figures 4th 
Edition, 2018). In 2019, an estimated 606,880 people are predicted to die of cancer in the 
United States (American Cancer Society: Cancer Facts & Figures, 2019). The cancer 
death rate in the United States reached its highest point in 1991 after being fueled for 
many years by the widespread use of tobacco products. Advancements in cancer 
screening and treatment, as well as increased awareness of cancer-causing agents, such as 
tobacco, have fostered a gradual decline in the cancer death rate since its peak in the early 
1990s. 
Cancer is treated using a variety of methods, such as chemotherapy, hormone 
therapy, immunotherapy, radiation therapy, and surgery. While many negative side-
effects are reported by patients undergoing cancer treatment, fatigue is the most prevalent 
(Morrow, Andrews, Hickok, Roscoe, & Matteson, 2002). Symptoms of cancer-related 
fatigue (CRF) have been reported by 50-90% of cancer patients worldwide (Mohandas, 
Jaganathan, Mani, Ayyar, & Rohini Thevi, 2017). It has been suggested that CRF may 






extent (Irvine, Vincent, Bubela, Thompson, & Graydon, 1991). Some of the most 
common symptoms experienced by patients with CRF are physical fatigue, mental 
fatigue, inability to concentrate, pain, stress, and nausea, which can all negatively impact 
quality of life, daily activities, and self-sufficiency (Mohandas et al., 2017).  
Chemotherapy and Doxorubicin (DOX) 
Chemotherapy is a type of cancer treatment that affects the entire body rather than 
a localized area, as radiation therapy does. This attribute is ideal for individuals with 
metastasized cancers and for patients whose objective is to eradicate, control the spread 
of, or alleviate symptoms caused by the cancer (American Cancer Society: 
Chemotherapy- What It Is, How It Helps, 2018). Anthracyclines are among the most 
successful chemotherapeutic drugs due to their efficacy in treating most cancers (Weiss, 
1992). Doxorubicin (DOX), also known as Adriamycin, and daunorubicin (DNR) are two 
anthracycline anti-tumor antibiotics that were first isolated in 1967 from the Streptomyces 
peucetius bacterium species (Bonadonna et al.,1969). The single molecular variance 
between DOX and DNR lies in the side chain, by which the actions of the two drugs are 
differentiated (Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004). While DNR 
treatments are utilized primarily for fighting certain leukemias, DOX treatments are ideal 
for combatting a variety of cancers such as lymphoma, leukemia, and neuroblastoma, as 
well as lung, thyroid, ovarian, bladder, and stomach cancer. Based on its intended target, 
DOX can be injected intravenously or intraperitoneally for the treatment of various 
cancers.  
Although the exact mechanisms remain unclear, there are two probable ways in 






to prevent an enzyme, topoisomerase-II, from disentangling deoxyribonucleic acid 
(DNA) strands, which ultimately leads to DNA damage and cell death (Thorn et al., 
2011) and 2) DOX presence in the cell causes free radical formation, which leads to an 
imbalance in the ability of the cell to detoxify intermediates, disruptions in cell signaling, 
and damage to the cell membrane (Gewirtz, 1999). While treatment with DOX can be 
helpful in disrupting and preventing certain types of cancer growth and is sometimes 
necessary for survival, it can harm and inflict damage to many physiological processes in 
the body that were functioning normally and healthily prior to treatment.  
Doxorubicin (DOX)-Induced Toxicities 
While DOX treatment may provide anti-cancer benefits over a wide range of 
action, a major shortcoming of DOX treatment is the toxicity inflicted on the patient. 
DOX-mediated toxicity has a direct relationship to the treatment dose and can impair 
functioning of the heart, brain, liver, and kidneys (Carvalho et al., 2009). This damage 
may lead to other malignancies in the body, such as cachexia, myotoxicity, cytotoxicity, 
muscle fatigue, muscle dysfunction, and cardiotoxicity, among others. The standard used 
to predict the degree of toxicity from DOX treatment is the total dose administered to the 
patient (Thorn et al., 2011). For this reason, the dose administered to each individual 
undergoing treatment should be methodically and vigilantly considered (Carvalho et al., 
2009). 
 One of the primary motives for the dose-limited administration of DOX is its 
ability to induce long-lasting and severe cardiotoxic effects (Carvalho et al., 2009). The 
heart is especially susceptible to DOX-induced toxicity for several reasons, but one of the 






heart (Nohl, 1987). This generation of ROS is compounded because cardiomyocytes have 
a higher density of mitochondria per unit volume in comparison to other tissues 
(Berthiaume & Wallace, 2007) in combination with lower levels of antioxidant enzymes 
(Odom, Hatwig, Stanley, & Benson, 1992). Amelioration of cells following DOX-
induced damage is problematic because only half of cardiomyocytes are renewed 
throughout the lifespan (Carvalho & de Carvalho, 2010). It has also been suggested by 
Damiani et al. (2016) that damage induced from DOX may be caused by an interaction of 
the drug and iron, which leads to increased ROS generation and the eventual impairment 
of mitochondria. Moreover, Damiani et al. (2016) highlighted that treatment with DOX 
causes an interference with redox cycling, which has the potential to influence other 
physiological processes and lead to heart failure.  
Cachexia 
 Cachexia is a complex metabolic condition that is associated with underlying 
diseases, illnesses, or medical conditions such as chronic obstructive pulmonary disease 
(COPD), multiple sclerosis, chronic heart failure, and cancer, among others (Aoyagi, 
Terracina, Raza, Matsubara, & Takabe, 2015). Cancer cachexia is characterized by a 
progressive and involuntary loss of lean body mass, with or without fat mass loss, that 
cannot be completely ameliorated with nutritional interventions (Fearon et al., 2011). 
Some evidence suggests that chemotherapy drugs, such as DOX, may play a role in 
promoting cachexia development, but the exact mechanisms leading to this association 
are yet to be fully elucidated (Pin, Barreto, Couch, Bonetto, & O’Connell, 2019). Pin et 
al. (2019) utilized two murine models of cancer-induced and chemotherapy-induced 






For the first time, it was demonstrated that there are differences in metabolic 
derangements based on the cause of cachexia, which indicated that therapeutic treatments 
should highlight these variances. For example, there was a significant increase in low-
density lipoprotein particles only in the cancer-induced cachexia model, while elevated 
skeletal muscle ROS were observed in both the cancer- and chemotherapy-induced 
cachexia models.  
Several factors other than those pertaining to nutrition have been explored as 
mediators of skeletal muscle atrophy in cachexia, because cachexia may occur even in 
circumstances of normal energy intake and expenditure (Tisdale, 1999). Some of the 
investigated factors, such as cytokines and elements of tumors, have the ability to 
mobilize amino acids from skeletal muscle tissue and fatty acids from adipose tissue. 
This may account for the dramatic losses in muscle and, sometimes, fat mass that are 
observed in individuals with cachexia. Barreto et al. (2016) reported that chemotherapy in 
mice may have instigated changes in mitochondrial functioning and expression, which 
may have contributed to the muscle wasting observed following treatment. Similarly, 
Gilliam et al. (2013) observed that skeletal muscle mitochondria were a main source of 
oxidants and that treatment with DOX in rats disrupted mitochondrial functioning. It was 
suggested that there was an increase in ROS as a result of this disturbance, which offered 
a potential explanation for the decreased energy expenditure and respiratory capacity that 
was noted by Gilliam et al. (2013). Furthermore, Fabris and MacLean (2018) were the 
first to report that DOX administration affects amino acid concentrations in skeletal 
muscle, the vasculature, and the space between the skeletal muscle and vasculature. A 






skeletal muscle into the vasculature was reported. These findings indicated that amino 
acid metabolism may be a factor involved in cachexia, in relation to protein synthesis and 
degradation and should be a future therapeutic target in chemotherapy patients. 
 Attempts have been made in several studies to prevent chemotherapy-induced 
cachexia by blocking certain mechanisms of the pathways that allow for skeletal muscle 
loss. Hulmi et al. (2018) were the first to compare the effects of blocking activin receptor 
type IIB (ACVR2B-Fc), by treatment with a soluble ligand binding domain, on 
components of cachexia in skeletal and cardiac muscle tissue following DOX 
administration. Blocking ACVR2B-Fc ligands led to a significant decrease in skeletal 
muscle wasting, but only slightly decreased cardiac muscle atrophy. While cardiac and 
skeletal muscles exhibited similar wasting due to DOX treatment, changes in 
transcriptional factors were most noticeable in skeletal muscle. One plausible explanation 
for this dissimilarity may be related to the gene expression of myostatin, which was 18 
times higher in the skeletal muscle compared to cardiac muscle. Gene expression of 
myostatin, an ACVR2B ligand, can directly affect regulator factors of the cell cycle, such 
as the inhibitory protein p21 (Patel, A., Tripathi, Patel, U., Shah, & Joshi, 2014).  
Fatigue and Dysfunction 
In addition to cachexia, treatment with DOX has caused both generalized and 
skeletal muscle fatigue, muscle dysfunction, and damage to a variety of tissues. 
According to Miller et al. (2007), over half of a sample of chemotherapy patients reported 
generalized fatigue that lingered for weeks following treatment. Moreover, skeletal 
muscle atrophy has been correlated with increased rates of disease and death among 






importance of understanding the mechanisms responsible for the presentation of fatigue 
and atrophy of individuals undergoing chemotherapy treatments.  
 Increased fatigability and atrophy of skeletal muscle following DOX 
administration has been reported in both animals and humans. For instance, ex vivo 
maximal force, rate of contraction, and relaxation velocity were compromised in the EDL 
muscle of mice following two hours of incubation with DOX (van Norren et al., 2009). 
Also, van Norren et al. (2009) observed that the calcium (Ca2+) response of C2C12 
myotubes previously incubated with DOX was altered after stimulation with caffeine or 
ATP. Stimulation of the C2C12 myotubes in vitro with caffeine and ATP caused marked 
increases in Ca2+ influx, which demonstrated that DOX treatment influences Ca2+ 
handling and, therefore, impacts muscular contraction. As reported by Nguyen et al. 
(2016), coadministration of DOX with Ca2+ resulted in a drastically higher rate of cell 
survival compared to cells treated only with DOX. Also, Ca2+ presence played a role in 
the suppression of DOX cytotoxicity in human breast cancer cells. This finding is 
especially relevant to individuals treated with DOX who are simultaneously administered 
another drug or dietary supplement that alters Ca2+ levels. For example, Vitamin D 
supplementation may increase Ca2+ concentrations in the body (Lips, 2012) and may, 
therefore, influence the efficacy of DOX treatment. 
Skeletal muscle dysfunction is a common consequence of chemotherapy 
treatment, as observed in animals and humans, and occurs through a variety of 
mechanisms and mediators. One potential mediator of muscle contractile dysfunction is 
tumor necrosis factor-alpha (TNF-α), a cytokine that promotes inflammation. Gilliam et 






and absolute force production as well as earlier exhaustion of the EDL muscle under a 
fatigue protocol. Additionally, elevated concentrations of TNF-α were observed 72 hours 
following injection with DOX. To investigate whether the observed dysfunction was 
mediated by TNF-α and TNF-α receptor 1, the same experiment was repeated with mice 
lacking ample amounts of TNF-α receptor 1. While time to fatigue was not significantly 
altered, the decrease in maximal specific force production caused by DOX injection was 
averted in mice with the TNF-α receptor 1 deficiency. Based on these results, Gilliam et 
al. (2009) were the first to suggest targeting the TNF-α and TNF-α receptor 1 signaling 
pathway as a potential therapeutic intervention for chemotherapy patients to attenuate 
muscle dysfunction. 
It is unclear if the degree of skeletal muscle dysfunction and myotoxicity 
commonly observed following DOX treatment is related to that of cardiotoxicity. Hydock 
et al. (2011) were the first to investigate the effects of three different doses of DOX on 
EDL and SOL muscle dysfunction in rats five days following injection and compared the 
outcomes to those of DOX on cardiac dysfunction. Treatment with all three doses of 
DOX led to a fatigue pattern where the SOL muscle, which is composed primarily of 
slow-twitch fibers, contracted with significantly less force compared to baseline measures 
at roughly 40 to 50 seconds earlier than control. However, DOX treatment did not cause 
the same decline in fatigue resistance in EDL muscle, comprised mostly of fast-twitch 
fibers, where contraction force was only significantly less than baseline 20 seconds 
earlier than control at most. There was variation between DOX doses in contraction force 
of both SOL and EDL muscles under the fatigue protocol, which indicated that DOX-






was impaired in the heart to the same extent as SOL muscle, which highlighted the 
relationship between cardiac dysfunction and DOX treatment in contributing to the 
decline in skeletal muscle function. 
While the dose-dependent relationship of DOX administration on skeletal and 
cardiac muscle dysfunction was identified by Hydock et al. (2011), a time-dependent 
gradual increase in muscle dysfunction in rats was observed by Hayward et al. (2013) 
one-, three-, and five-days post-injection with DOX. Accumulation of DOX was different 
in smooth, skeletal, and cardiac tissue, but was the greatest in cardiac tissue one-day post-
treatment and steadily declined over the course of the five-day study period. Decline in 
contractile function of the SOL and EDL muscles was similar even though there was a 
significant difference in DOX accumulation. Moreover, this was the first study to 
quantify DOX in vascular tissue as well as describe changes in accumulation over time. 
Taken together, these findings indicated that interactions between physiological factors, 
rather than DOX accumulation alone, may influence muscle dysfunction, such as those 
between cardiac muscle, the vasculature, and skeletal muscle (Hayward et al., 2013).  
Cardiotoxicity 
The effects of DOX administration on physiological processes in the human body 
have been widely investigated, especially those pertaining to cardiotoxicity. Cardiac 
dysfunction is the most severe side effect of DOX treatment and can ultimately lead to 
heart failure (Zhang, Shi, Li, & Wei, 2009). Specifically, long-term toxicity in the heart 
leads to dysfunction of the left ventricle, which can progress to congestive heart failure 
(Slørdal & Spigset, 2006). The risk for developing congestive heart failure following 






Jassem, 2011), but the dose-response relationship pertaining to cardiotoxicity may 
fluctuate between individuals (Khakoo & Yeh, 2008). Potential mechanisms of DOX 
cardiotoxicity have been explored but are yet to be fully understood. He et al. (2018) 
created a physiologically-based pharmokinetic (PBPK) model to measure the outcomes 
of DOX administration in as broad of a context as its effects on physiological systems to 
a narrow focus on its effects in organelles of the cell. The PBPK model utilized by He et 
al. (2018) pointed to oxidative stress as the principal mechanism for DOX-induced 
cardiotoxicity in humans. 
Oxidative Stress and Reactive Oxygen Species (ROS)  
Oxidative stress occurs when there is a disruption in the balance between ROS 
creation and antioxidant protections. The stability of molecules is decreased if they 
possess unpaired electrons, which is a defining quality of free radicals (Betteridge, 2000). 
This attribute causes free radicals to be highly reactive, with some possessing potencies 
higher than others. While oxidative stress cannot be measured directly, it can be 
measured through the quantification of oxidative damage products, such as those 
resulting from protein oxidation, lipid peroxidation, and DNA oxidation (Betteridge, 
2000).  
Skeletal muscle proteolytic pathways are highly influenced by the presence of 
ROS, which partially encourage protein breakdown in muscle by activating protein 
degradation systems, such as the ubiquitin-proteasome pathway. One of the main sources 
of ROS is nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, also known 






numerous subunits that constitute elements of the cell membrane and cytosol and is 
partially responsible for ROS production.  
It is well-established that the over-expression of transforming growth beta factor 
(TGF-β), a regulator of inflammation and fibrosis in several tissues, contributes to muscle 
degradation and decline of myosin and actin, contractile proteins. Narola, Pandey, Glick, 
and Chen (2013) demonstrated that an over-expression of transforming growth factor 
beta 1 (TGF-β1) caused skeletal muscle atrophy in mice, with the degree of muscle 
wasting being directly related to the total TGF-β1 and endogenous TGF-β1 expression. 
Mendias et al. (2011) measured the contractility of the EDL muscle in mice in vitro five 
days following injection with TGF-β. Following injection, whole muscle and individual 
muscle fiber cross-sectional area was significantly decreased together with maximum 
isometric force production. TGF-β treatment also increased atrogin-1 expression in the 
tibialis anterior muscles, which was anticipated.  
While it is well-known that TGF-β causes skeletal muscle atrophy, the exact 
mechanisms of this relationship remain undetermined. However, Abrigo, Rivera, Simon, 
Cabrera, and Cabello-Verrugio (2016) were the first to state that TGF-β exposure 
stimulated NOX-induced ROS production. This finding helped to establish a component 
of the mechanism for skeletal muscle atrophy. Moreover, markers of muscle atrophy 
elicited by TGF-β1 were lessened when cells were treated with NOX inhibitors or 
antioxidants. Taken together, these findings provide insight as to the potential mechanism 
of skeletal muscle atrophy induced by TGF-β presence in skeletal muscle tissue and offer 
targets for therapeutic intervention in individuals with diseases that induce skeletal 






If antioxidant defenses are weakened as a result of cancer treatment, for example, 
tissue damage may occur. Drugs typically used in cancer treatments, such as DOX, alter 
the structure of myosin and impair mitochondria while concurrently increasing ROS 
production (Carvalho et al., 2009). In addition to structure being altered, a decrease in 
overall myosin expression in C2C12 murine myotube cell cultures has been observed 
following DOX treatment (Guigni et al., 2018). Co-administration of DOX with MitoQ, 
an antioxidant that targets mitochondria, inhibited the reduction of myosin expression, 
loss of mitochondria, and creation of ROS previously observed in murine C2C12 
myotubes by Guigni et al. (2018). Similarly, Gilliam et al. (2012) treated C2C12 
differentiated myotubes with DOX and observed an approximate 50% decrease in myosin 
and actin expression. Oxidant activity in the cytosol of myotubes was elevated only hours 
following DOX treatment and expression of ubiquitin ligases, MuRF-1 and MAFbx, was 
significantly increased 24 hours post-treatment. Involvement of mitochondria in this 
process was verified by the administration of a peptide antioxidant, capable of 
permeating the cell, that concentrated in the inner membrane of the mitochondria and 
improved mitochondrial functioning, similar to the technique used by Zhao et al. (2004). 
In agreement with Gilliam et al. (2012), Min et al. (2015) reported that treatment 
with a specific peptide in the mitochondria is capable of inhibiting DOX-induced 
dysfunction. Moreover, increased creation of oxidants by mitochondria encourages the 
development of, and is necessary for, skeletal and cardiac muscle dysfunction (Min et al., 
2015). Treatment of the myotubes with the antioxidant by Gilliam et al. (2012) also 
prevented expression of the ubiquitin ligases, which indicated that DOX utilized ROS in 






Negative Regulators of Muscle Growth 
Myostatin 
TGF-β is a multifunctional cytokine and main inhibitor of myogenesis (Hodgson, 
Mafi, R., Mafi, P., & Khan, 2018). Myostatin belongs to the TGF-β superfamily of cell 
regulatory proteins and is essential to the proper regulation of skeletal muscle 
hypertrophy in mammals (Ríos, Fernández-Nocelos, Carneiro, Arce, & Devesa, 2004). 
Also known as growth differentiation factor-8 (GDF-8), myostatin is created and released 
by myocytes that negatively regulate skeletal muscle mass. Unlike other members of the 
TGF-β family, myostatin is confined solely to the skeletal muscle tissue during 
development (Ríos, Carneiro, Arce, & Devesa, 2002).  
Components of muscle atrophy, such as muscle denervation and disuse, have been 
associated with an increase in myostatin expression in skeletal muscle tissue (Delfino et 
al., 2013). McPherron, Lawler, and Lee (1997) first identified GDF-8 and determined its 
expression was specific to both developing and adult skeletal muscle. Following 
myostatin disruption in mice, McPherron et al. (1997) also concluded that a combination 
of muscle cell hypertrophy and hyperplasia encouraged the dramatic increase in skeletal 
muscle mass. Certain genetic mutations have been identified in mice and cattle where 
myostatin was essentially non-existent or non-functioning in the muscle tissue. These 
circumstances resulted in muscle doubling and unregulated muscle growth (Kambadur, 
Sharma, Smith, & Bass, 1997). Zimmers et al. (2002) were able to induce a condition in 
adult mice similar to cachexia, where significant losses in fat and muscle mass were 
detected following injections of circulating myostatin into the thighs. This observation 






Similar to other regulatory proteins belonging to the TGF-β family, myostatin 
signals to the muscle cell with the assistance of a receptor complex comprised of the 
activin type I and type II receptors (Ríos et al., 2004). Myostatin shares the receptor pair 
with other members of the TGF-β family, which suggests that there is a mechanism that 
restricts myostatin actions to the muscle cell. The signaling pathway utilized by 
myostatin involves the binding of myostatin directly to one of the activin type II receptors 
(Rodriguez et al., 2014). This binding leads to the activation of the type I receptors and 
eventual activation of Smad proteins. Following activation, Smad proteins translocate 
into the nuclei of cells, prompting gene transcription and interactions with promoter DNA 
sequences (Derynck, Zhang, & Feng, 1998). Moreover, Taylor et al. (2001) observed that 
myostatin partially controls muscle mass by preventing growth and regeneration through 
the inhibition of DNA and protein synthesis. Overall, myostatin acts through several 
interactions with other proteins and signaling pathways to regulate skeletal muscle 
growth.  
Joulia et al. (2003) provided data which indicated that MyoG, one of the MRFs, is 
likely a main target of endogenous myostatin. An overexpression of myostatin influenced 
myogenic protein factor levels, which signified the potential for myogenin transcription 
influence. However, Ríos et al. (2002) found that an overexpression of myostatin 
specifically downregulates messenger ribonucleic acid (mRNA) levels of positive 
regulatory factors of muscle mass, thus inhibiting muscle growth. Furthermore, Joulia et 
al. (2003) determined that p21 is an additional target of myostatin. This conclusion was in 
agreement with that of Thomas et al. (2000), who suggested that an increase in p21 






It has been well-documented that myostatin directly regulates the formation of 
excess fibrous connective tissue in skeletal muscle, which can lead to scarring and 
hardening of the tissue. Muscle tissue fibrosis is attributed to an excess deposition of 
collagen, along with other extracellular matrix (ECM) components, by muscle fibroblasts 
(Wynn, 2008). Li, Kollias, and Wagner (2008) observed that myostatin induced the 
production of ECM proteins, such as collagen, both in vitro and in vivo, and that 
myostatin directly regulated muscle fibroblasts and myocyte growth. This finding offered 
support for myostatin knockout models as future research interests to treat diseases 
associated with skeletal muscle fibrosis.  
Increasing muscle mass and strength, which has been demonstrated after the 
inhibition of myostatin activity, could be an effective method for researching the 
potential treatment of several degenerative muscle diseases (Tobin & Celeste, 2005). 
Several studies have utilized myostatin knockout models and myostatin inhibitory models 
to research prospective treatments for individuals with degenerative muscle diseases. For 
the first time, Whittemore et al. (2003) demonstrated that skeletal muscle mass and grip 
strength were increased following treatment with an inhibitory antibody to myostatin. Lin 
et al. (2002) were the first to report that an inhibition of ligands of the myostatin family, 
using two models of cancer cachexia, significantly increased muscle mass in adult mice. 
There was as much as a 40% increase in the muscle mass of the myostatin-family ligand-
inhibited mice compared to control mice. This result offered support for the future use of 
cancer cachexia models in the continued exploration of therapeutic treatments for 






In a study which utilized the mdx mouse model of DMD, an inherited disease of 
progressive muscle degeneration, myostatin inhibition in vivo attenuated the dystrophic 
phenotype (Bogdanovich et al., 2002). Over a period of three months, myostatin 
inhibition was completed by means of intraperitoneal injections of blocking antibodies. 
This resulted in a decrease in muscle breakdown and an increase in body weight, absolute 
muscle strength, muscle mass, and muscle hypertrophy. In a similar limb-girdle muscular 
dystrophy model by Bogdanovich, McNally, and Khurana (2008), myostatin blockade 
resulted in gains in muscle mass, size, and absolute force. However, there were no 
significant improvements in the histology of the skeletal muscle tissue. These 
observations indicated that limitations of therapeutic interventions exist depending on the 
severity of the degenerative muscle disease (Bogdanovich et al., 2008).  
The myostatin signaling pathway may be a desired target for therapeutic 
intervention, because gene inactivation and drug administration have successfully 
modulated the pathway in favor of reducing the negative effects of cancer cachexia. The 
influence of TNF-α, a cachectic factor, on the myostatin signaling pathway was 
investigated by Costelli et al. (2008). Levels of myostatin and follistatin, an endogenous 
myostatin inhibitor, were elevated seven days following tumor transplantation into the 
gastrocnemius muscle of rats. Pentoxifylline (PTX), an anti-inflammatory drug that 
inhibits TNF-α, was administered to the tumor-bearing rats, which resulted in decreased 
myostatin expression after four days and increased follistatin activity after seven days. 
Similarly, Klimek et al. (2010) systemically administered Activin receptor extracellular 
domain/Fc fusion protein, ACVR2B-Fc, in an attempt to impede myostatin expression in 






unaffected while muscle atrophy was significantly prevented. Moreover, Gallot et al. 
(2014) employed myostatin gene inactivation in tumor-bearing mice, which prevented the 
expression of MuRF-1 and muscle atrophy F-box (MAFbx), two ubiquitin ligases. 
Proteolytic pathway activation was hindered due to the inhibition of the ubiquitin ligases, 
which encouraged further investigation of these pathways.  
Ubiquitin Ligases 
The ubiquitin-proteasome system is the primary regulatory mechanism of protein 
degradation in skeletal muscle and is highly influenced by muscle-specific ubiquitin-
ligase enzymes, such as MuRF-1 and MAFbx, also known as atrogin-1. Expression of 
MuRF-1 and MAFbx has been upregulated in at least 13 models of skeletal muscle 
atrophy and is a notable component of many physiological conditions and chronic 
diseases pertaining to muscle disuse (Clarke et al., 2007). Common human pathologies 
associated with muscle atrophy, and its correlation to MuRF-1 and MAFbx expression, 
are chronic kidney disease, diabetes, cancer cachexia, chronic obstructive pulmonary 
disease, and age-related muscle loss (Rom & Reznick, 2016).  
 MuRF-1 and MAFbx levels are promptly activated in several models of muscle 
atrophy, which denotes that these proteins may play a role in encouraging muscle wasting 
(Foletta, White, Larsen, Léger, & Russell, 2011). In animal models, muscle remodeling 
has been closely associated with the expression of MuRF-1 and MAFbx, which are 
influenced by numerous lifestyle factors, such as alcohol consumption, physical activity, 
smoking, and diet (Rom & Reznick, 2016). Several agents have demonstrated an ability 
to lessen the severity of muscle atrophy through the inhibition of MuRF-1 or MAFbx 






nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway (Rom & 
Reznick, 2016). Oxidative stress and inflammatory cytokines, such as interleukin-1 (IL-
1), have demonstrated an ability to activate the p38 MAPK and NF-κB pathways. 
Moreover, TNF-α and IL-1 activate the NF-κB pathway, which prompts skeletal muscle 
degradation via the transcriptional upregulation of MuRF-1. Both TNF-α and IL-1 
activate the p38 MAPK pathway, which stimulates MAFbx expression (Glass, 2005).  
While the role of ubiquitin ligases in skeletal muscle atrophy has been well-
established, their involvement in cancer cachexia remains largely unexplored. 
Mechanisms of muscle atrophy were studied by Yuan et al. (2015) in a colon cancer 
cachexia mouse model and C2C12 cells were also treated with TNF-α. Expression of 
MuRF-1 and atrogin-1 in the skeletal muscle of individuals with malignant and benign 
disease were analyzed. Ubiquitin ligases were upregulated during cancer cachexia in the 
mouse model, while a statistically significant excess of atrogin-1 expression was 
observed in the C2C12 cells. A knockdown of atrogin-1 by small interfering RNA 
demonstrated a protective effect on the C2C12 cells from TNF-α, which indicated that 
atrogin-1 may be a therapeutic target for treating muscle atrophy in individuals with 
cancer cachexia and warrants further investigation (Yuan et al., 2015). 
Myogenic Regulatory Factors (MRFs) 
 Approximately 50% of adult human body mass is comprised of skeletal muscle 
tissue (Zanou & Gailly, 2013). Skeletal muscle has the ability to regenerate in the event 
of damage. This tissue damage ranges in severity from small tears, due to daily activity, 
to acute muscle loss in cases of degenerative muscle disease or trauma. Regeneration 






activate in response to stimuli, such as damage (Zanou & Gailly, 2013). When prompted, 
satellite cells express transcription factors belonging to the MRF family: Myogenic 
Factor 5 (MYF5), Myogenic Differentiation (MyoD), Myogenin (MyoG), and Myogenic 
Regulatory Factor (MRF4) (Zammit, 2017). These positive regulators of muscle mass 
play a key role in muscle tissue growth by controlling phases of development and guiding 
myoblast proliferation and differentiation into multinucleated single muscle cells (Zanou 
& Gailly, 2013).  
Insulin-like Growth Factor 1 (IGF-1) 
Insulin-like growth factor (IGF-1) is a protein that encourages muscle growth in 
childhood and induces anabolic effects in the skeletal muscle tissue of adults. Myogenic 
differentiation, a process that results in mature skeletal muscle formation, is primarily 
regulated by myostatin and IGF-1 (Retamales, et al. 2015). Insulin-like growth factors 
(IGFs), alongside MRFs, are essential to muscle repair (Zanou & Gailly, 2013). 
Furthermore, expression of IGFs is controlled, in part, by MRFs and stimulation of IGFs 
induces MRF activity.  
A variety of growth factors are released during the repair of muscle tissue. Among 
these growth factors, IGFs solely encourage myocyte growth and differentiation (Zanou 
& Gailly, 2013). IGF-1 activates the phosphatidyl-inositol 3-kinase (PI3K)-Akt pathway, 
which prompts skeletal muscle hypertrophy and is necessary during tissue repair (Glass, 
2003). In addition to activating the PI3K-Akt pathway, IGF-1 also inhibits specific 
factors that negatively impact muscle growth and encourage skeletal muscle wasting. Stitt 






with MuRF-1 and MAFbx. Glass (2005) agreed that transcriptional upregulation of the 
ubiquitin ligases, MURF-1 and MAFbx, may be inhibited by IGF-1.  
The findings of Retamales et al. (2015) provided evidence of cross-talk between 
IGF-1 and myostatin signaling pathways. Incubation of skeletal myoblasts with myostatin 
resulted in a significant increase in the ratio of phosphorylated Smad3 (pSmad3) to 
Smad3. This effect was prevented when myostatin was incubated with a Smad3 inhibitor. 
Myoblasts incubated with myostatin expressed a significantly lower MyoD expression 
and decreased fusion of myoblasts, which indicated a dependence of signaling on Activin 
receptor-like kinase/Smad3 (Retamales et al., 2015). Furthermore, pre-incubation of 
skeletal myoblasts with IGF-1 prevented the increased ratio of pSmad3:Smad3 that was 
demonstrated following myostatin incubation. Pre-incubation with IGF-1 also impeded 
the previously observed inhibitory effect of myostatin on MyoD levels. Lastly, in 
myoblasts preincubated with IGF-1 and treated with myostatin, the interaction of Smad3 
and Akt was greater than the interaction observed following IGF-1 preincubation alone. 
Taken together, the results of Retamales et al. (2015) indicate that there is cross-talk 
between growth proteins and that the IGF-1/PI3K/Akt pathway prevents myostatin 
signaling during myoblast differentiation.  
Forkhead Box O (FoxO) 
 Forkhead box O (FoxO) transcription factors are involved in numerous signaling 
pathways and play key roles in regulation, cell fate decisions, and tumor suppression (Fu 
& Tindall, 2008). Regulated by growth factors and stress, FoxO transcription factors are a 
subfamily of the fork head transcription factor family and are also involved in muscle 






muscle atrophy, Sandri et al. (2004) found that atrogin-1 transcription was curbed and 
phosphorylated FoxO1, FoxO3, and FoxO4 concentrations were elevated. This 
suppression of atrogin-1 in the cell models was controlled by the PI3K/Akt pathway. 
Sandri et al. (2004) also determined that atrogin-1 expression in the skeletal muscle tissue 
of adult mice was subdued by Akt activity, which involved the inactivation of FoxO 
transcription factors. Moreover, Stitt et al. (2004) stated that FoxO inhibition was 
necessary for the IGF-1/PI3K/Akt pathway to prevent the expression of the ubiquitin 
ligases, MuRF-1 and MAFbx, and thus, block atrophy activity. FoxO3 is negatively 
regulated by the NF-κB pathway, which is triggered by the presence of inflammatory 
cytokines (Schiaffino, Dyar, Ciciliot, Blaauw, & Sandri, 2013). There is a highly-
coordinated feedback loop between FoxO proteins and reactive oxygen species (ROS), 
also known as free radicals (Farhan et al., 2017). Inhibition of FoxO transcription factors, 
therefore, may be a practical approach to encourage anti-atrophy activity. 
Dexamethasone (DEX) 
Glucocorticoids are steroid hormones that mediate muscle loss in several 
catabolic states. Dexamethasone (DEX), a synthetic glucocorticoid, may be used by 
individuals to control inflammation resulting from a variety of conditions (Assali, 
Shawahna, Dayyeh, Shareef, & Alhimony, 2018). For example, DEX is sometimes 
administered following chemotherapy to curb the negative side effects of treatment, such 
as inflammation and nausea.  
High doses and chronic use of glucocorticoids can lead to losses in skeletal 
muscle strength and mass due to increases in myofibrillar protein degradation and 






MuRF-1 and MAFbx in a mouse model has spared muscle mass specifically following 
muscle denervation, but the role of the ubiquitin ligases in atrophy-inducing conditions is 
less certain (Baehr, Furlow, & Bodine, 2011). Baehr et al. (2011) determined that mice 
with a MuRF-1 deletion had more muscle mass sparing compared to control mice 
following two weeks of DEX treatment. This result indicates that the principal role of 
MuRF-1 may be something other than regulating protein degradation. However, there 
was no evidence that the MAFbx deletion attenuated muscle mass losses when compared 
to control mice. These findings support the concept that MuRF-1 and MAFbx may 
function dissimilarly under different atrophy models (Baehr et al., 2011). 
The role of myostatin in the skeletal muscle tissue in potentially aiding muscle 
atrophy following treatment with DEX has also been investigated. Allen & Loh (2011) 
demonstrated that myostatin mRNA levels were doubled in fast-twitch skeletal muscle 
fibers in mice following DEX injection in vivo. Similarly, Gilson et al. (2007) 
demonstrated that there was an increase in the mRNA of enzymes involved in protein 
breakdown following DEX treatment in mice. Moreover, DEX treatment did not 
significantly impact mRNA levels in myostatin knockout mice, which indicated that 
myostatin omission prevents skeletal muscle atrophy in mice treated with DEX. 
Administration of DEX has also been associated with an upregulation of myostatin gene 
expression in mice (Qin et al., 2013). 
Myosin heavy chain (MHC), the motor protein of the thick filaments in skeletal 
muscle, has multiple isoforms with different characteristics utilized in muscle function 
modulation (Wells, Edwards, & Bernstein, 1996). It is well established that DEX 






that DEX treatment prompted a loss of MHC protein in avian fast-twitch skeletal 
myofibers in vitro that was attenuated by mechanical stimulation. Research pertaining to 
the effects of DEX treatment on MHC was advanced by Clarke et al. (2007), where 
C2C12 myotubes were treated with the synthetic glucocorticoid DEX for one day. There 
was a loss of MHC protein and an increase in MuRF-1, as well as evidence that MHC 
physically associates with MuRF-1 in the skeletal muscle. Therefore, MHC protein 
expression was preserved through the inhibition of MuRF-1 in mice treated with DEX 
(Clarke et al., 2007). Castillero, Alamdari, Lecker, and Hasselgren (2013) provided 
evidence for a compensatory mechanism that regulates the ubiquitin ligases, since 
suppression of atrogin-1 elicited augmented expression of MuRF-1, and vice versa, 
following DEX treatment. Furthermore, the findings of Castillero et al. (2013) provided 
support for the hypothesis that both MuRF-1 and atrogin-1 expression must be inhibited 
to prevent the muscle atrophy and protein degradation that occur as a result of DEX 
treatment.  
Creatine Supplementation 
Creatine is a substance that is naturally synthesized in the human body by the 
liver and plays an important role in facilitating energy provision during muscular 
contraction (Fairman et al., 2019). In addition to being formed in the body, creatine can 
be obtained in the diet from certain meats and fish. Dietary supplementation is the most 
efficient way to increase creatine stores in both skeletal muscle and the brain (Riesberg et 
al., 2016). Roughly 95% of creatine is located in the skeletal muscle tissue and the 
remaining approximate 5% is distributed amongst the brain, kidneys, and testes 






creatine in the skeletal muscle tissue is in the form of PCr, while the other approximate 
one-third is in the form of free creatine (Wyss & Kaddurah-Daouk, 2000).  
Energy for muscular contractions is acquired from PCr, a phosphorylated creatine 
molecule, and ATP, an organic chemical (Banerjee et al., 2010). At rest, ATP is produced 
in the mitochondria through oxidative phosphorylation. However, short-duration, high-
intensity resistance exercises rely on the phosphagen system for ATP production in 
maximal efforts lasting less than 10 seconds, while anaerobic glycolysis is utilized for 
energy production between 10 and 30 seconds (Hall & Trojian, 2013). In a reaction 
catalyzed by phosphoryl creatine kinase (CK), ATP is used to convert creatine to PCr in 
the sarcoplasm of the muscle cell (Andres et al., 2017). The reverse of this reaction is 
utilized to provide additional ATP in situations that necessitate a higher ATP demand, 
such as the muscular contraction required during exercise or physical activity (Poortmans 
et al., 2010). Based on these mechanisms, creatine may also function to uphold a pool of 
PCr to be utilized for energy needs.  
Creatine supplementation is successfully used as an ergogenic aid for activities 
that involve repeated bouts of high-intensity exercise. This is not only due to the increase 
in PCr stores available to be utilized, but also possibly because of increased rates of PCr 
resynthesis during rest and recovery (Lemon, 2002). Furthermore, the onset of fatigue 
may be delayed by increasing PCr stores through creatine supplementation, which may 
enhance performance during maximal-effort exercises. Several studies have reported that 
total creatine and PCr stores in skeletal muscle tissue were increased by supplementing 






per day (Hall & Trojian, 2013). Moreover, uptake of creatine into the muscle tissue was 
highest two days following the start of supplementation in a study by Harris et al. (1992).  
The most effective dosing for creatine supplementation involves a brief loading 
period followed by several weeks of a maintenance period. Although loading doses are 
the most constructive means of supplementation, they are not required to increase stores 
of creatine in skeletal muscle tissue (Hall & Trojian, 2013). According to Hultman, 
Söderlund, Timmons, Cederblad, and Greenhaff (1996), creatine loading could be 
accomplished in the average adult male by consuming a loading dose of 0.3 g of creatine 
per kilogram (kg) of body mass per day for between five and six days. An adequate 
maintenance dose following the loading period was 0.03 g of creatine per kg of body 
mass per day. Maintenance dosing is typically upheld for a period for four to six weeks 
depending on the intended goal of the individual (Hall & Trojian, 2013). Furthermore, 
supplementation with 2-5 g per day of pure creatine has been recommended in adults and 
older individuals as a preventative health measure. This is especially important in older 
and elderly adults, because these populations tend to eat less meat compared to the 
general population (Wallimann, Tokarska-Schlattner, & Schlattner, 2011). The largest 
and most long-term reported dose of creatine that has safely been consumed by healthy 
individuals, and even patient populations, of all ages was a maximum dose of 30 g per 
day for five years (Kreider et al., 2017). 
Aguiar, Januário, et al. (2013) were the first to exclusively examine long-term 
creatine supplementation in combination with 12 weeks of resistance training in healthy 
older females. Long-term creatine supplementation paired with resistance training 






Likewise, Candow et al. (2014) compared the outcomes of creatine supplementation in 
healthy older males and females before versus after supervised resistance training 
sessions for 12 weeks and was the first study to do so. Improvements in lean tissue mass, 
limb muscle hypertrophy, and muscular strength were comparable between groups, which 
indicated that timing of supplementation may not be as important in older individuals as 
in younger populations. However, Candow, Vogt, Johannsmeyer, Forbes, and Farthing 
(2015), who also utilized an older untrained participant population, concluded that 
resistance training elicited the greatest improvements in lean tissue mass when creatine 
was ingested immediately after training.  
As a potential therapeutic treatment, the effect of oral creatine supplementation on 
muscular strength in individuals with Duchenne muscular dystrophy (DMD) was 
investigated by Banerjee et al. (2010). Creatine supplementation led to a statistically 
significant increase in the ratio of phosphocreatine to inorganic phosphate, which 
indicated that there was an improvement in cellular energetics in individuals with DMD 
who received a standard dose of creatine once a day for eight weeks. Tarnopolsky et al. 
(2004) also investigated the effects of creatine supplementation in boys with DMD and 
found that four months of supplementation led to increases in fat-free mass. There was 
also a statistically significant increase in hand grip strength in the dominant hand of boys 
with DMD, but it is unclear if these results could be replicated in older individuals with 
DMD.  
Creatine supplementation has also shown to attenuate the adverse effects of 
damage caused by DOX treatment, cancer cachexia, and chemicals in a range of tissues. 






were protected from damage following creatine supplementation. Specifically, ROS 
production was significantly decreased, which implied that oxidative stress was also 
reduced. Relatedly, oxidative stress was prevented in tumor-bearing rats following 
supplementation with creatine in a study by Deminice et al. (2016). Progression of cancer 
cachexia was also inhibited following creatine supplementation, as determined by an 
approximate 30% average reduction in tumor weight compared to tumor-bearing 
controls. Campos-Ferraz et al. (2016) also reported an estimated 30% average decrease in 
tumor growth in tumor-bearing rats supplemented with creatine for 40 days compared to 
control rats. Moreover, there was also a trend toward a reduction in TNF-α in tumor-
bearing rats treated with creatine for 15 days compared to controls, similar to the findings 
of Cella et al. (2019).  
Norman et al. (2006) explored the effects of creatine supplementation on quality 
of life and muscle function in individuals undergoing chemotherapy treatment for 
colorectal cancer. Self-reported quality of life and muscle function were not improved 
following supplementation with creatine, but bioimpedance markers, such as capacitance, 
demonstrated favorable outcomes. Relatedly, a creatine loading protocol was utilized by 
Jatoi et al. (2017) to investigate its potential impacts on the severity of cancer anorexia 
and weight loss syndromes experienced by patients with terminal malignancies. Creatine 
supplementation did not have a protective effect in patients, as rates of unfavorable 
intervention-related events were comparable between both groups of patients.  
Creatine supplementation prior to treatment with DOX has protected skeletal 
muscle chemically- and DOX-induced damage and dysfunction. Chemically-induced 






by Cooke, Rybalka, Stathis, and Hayes (2018), which focused on the ability of creatine 
supplementation to attenuate the damaging effects of this medication. An intramuscular 
injection of bupivacaine typically causes the breakdown of nearly all fibers in the muscle, 
which may be permanent depending on the dosage (Rosenblatt & Woods, 1992). Cooke 
et al. (2018) found that creatine-supplemented EDL muscles exhibited a greater ratio of 
intact (non-damaged) fibers and greater cross-sectional areas of non-damaged fibers 
compared to controls seven days post-injection. Creatine-supplemented EDL muscles 
also produced higher magnitudes of absolute force in comparison to controls at fourteen 
days post-injection. Taken together, these findings indicated that creatine 
supplementation had a protective effect on EDL muscle following intramuscular injection 
with bupivacaine in rats, which may have clinical implications in treating various muscle 
diseases. Similarly, treatment with creatine prior to DOX administration ex vivo in rat 
skeletal muscle attenuated the muscle dysfunction in the EDL and SOL muscles typically 
caused by DOX treatment, as reported by Bredahl and Hydock (2017). Creatine 
pretreatment extended time-to-fatigue of DOX-treated SOL muscle and lessened the 
severity of force decline in DOX-treated EDL muscle. 
 Additionally, the effects of creatine supplementation in the DIA muscle have been 
researched in a variety of contexts. Menezes et al. (2007) investigated the effects of 
creatine supplementation on body mass, exercise performance, respiratory function, and 
DIA muscle fiber diameter and weight in rats following treatment with DEX. 
Simultaneous treatment with both creatine and DEX lessened the severity of the 
impairments, such as those on maximal oxygen consumption and maximum treadmill 






DEX alone. Tidal volume, the volume of air displaced between inhalation and exhalation, 
was elevated due to DEX treatment alone. Simultaneous treatment with creatine led to a 
significant decrease in the elevation, which indicated that there was a protective effect of 
creatine on respiratory function. Administration of DEX alone led to significant DIA 
muscle mass losses in comparison to controls, while treatment with creatine alone caused 
muscle mass gains in comparison to controls. Moreover, the simultaneous use of creatine 
with DEX lessened the severity of the DIA muscle weight losses caused by DEX. The 
findings of Menezes et al. (2007) show that creatine monohydrate supplementation 
attenuated the harmful effects of high-dose DEX on maximal exercise performance and 
DIA muscle mass. 
The effects of supplementing the diet of spiny mice with creatine during 
pregnancy on DIA muscle functioning in pups after birth was investigated by LaRosa et 
al. (2016) and Cannata et al. (2010). LaRosa et al. (2016) compared the effects of birth 
asphyxia on DIA muscle structure and function in pups from mothers supplemented with 
creatine during pregnancy to controls. There was a significant increase in the proportion 
of fast-twitch glycolytic fibers and a decrease in cross-sectional area of all muscle fiber 
types in the DIA following birth asphyxia in pups without maternal creatine 
supplementation. These outcomes were not observed in pups from mothers supplemented 
with creatine. Similarly, Cannata et al. (2010) explored the effects of maternal creatine 
supplementation on DIA muscle fiber contractile function and structure in pups, along 
with mRNA concentrations of the ubiquitin ligases, myostatin and MuRF-1. Cannata et 
al. (2010) reported a nearly 20% average decrease in cross-sectional area of muscle fibers 






al. (2016). This DOX-induced outcome pertaining to muscle fiber cross-sectional area 
was also attenuated by maternal creatine supplementation. Furthermore, myostatin and 
MuRF-1 mRNA levels were doubled following hypoxia-induced damage and maternal 
creatine supplementation lessened the severity of this consequence. 
 Likewise, Saremi et al. (2010) and Cella et al. (2019) focused on the effects of 
creatine supplementation on ubiquitin ligase expression. Following eight weeks of 
resistance training, serum myostatin levels in males were significantly decreased. 
Creatine supplementation in combination with resistance training led to a greater 
decrease in serum myostatin, which offers an explanation for the increased muscle mass 
also noted by Saremi et al. (2010). Cella et al. (2019) observed that creatine 
supplementation in tumor-bearing rats prevented the increase in MuRF-1 and atrogin-1 
levels shown in rats not treated with creatine. Additionally, the creatine treatment 
promoted lower levels of TNF-α, which implies that the negative consequences of the 
pro-inflammatory environment caused by tumor presence, such as ROS formation, were 
reduced.  
The effects of creatine supplementation on the musculoskeletal system have been 
thoroughly researched, but there is much less understanding of its possible influence on 
other physiological systems (Riesberg et al. 2016). A small amount of research has 
focused on the impact of creatine in neurological and immune system functioning, but its 
regulatory mechanisms have yet to be fully determined. Lawler, Barnes, Wu, Song, and 
Demaree (2002) were the first to report that creatine exhibited a statistically significant 
ability to act as a direct antioxidant scavenger against ROS and free radical ions. Lawler 






therapeutic interventions for individuals with neuromuscular diseases and similar 
syndromes.  
Furthermore, there is evidence to suggest that creatine may activate genes in the 
skeletal muscle tissue that are involved in several physiological processes (Safdar, 
Yardley, Snow, Melov, and Tarnopolsky, 2008). Safdar et al. (2008) were the first to 
report that a short-term creatine supplementation loading protocol activated genes that 
influenced osmosensing, metabolism, signal transduction, cell repair, and satellite cell 
proliferation and differentiation in the skeletal muscle tissue of young adult males. This 
observation may indicate that creatine influences regulatory proteins in skeletal muscle at 
a molecular level, especially since these effects were independent of any additional 
intervention pertaining to resistance training or diet. Taken together, these findings may 
provide insight as to the function of creatine in other physiological processes and 
influence future therapeutic treatments for individuals with physiological disorders and 
injuries.  
Exercise  
It is well-known that exercise stimulates the uptake of creatine into the skeletal 
muscle for utilization during muscular contraction (Wyss & Kaddurah-Daouk, 2000). 
This process occurs in all individuals at the onset of exercise, regardless of creatine 
supplementation status, and acts to prepare the body for performance. While the onset of 
physical activity causes creatine to be taken up by the skeletal muscle, exercise also 
induces the release of myokines from skeletal muscle into the circulation (Piccirillo, 
2019). These proteins are of particular importance because they assist in the regulation of 






cases of heart failure and cancer. Myokines act in an autocrine, endocrine, or paracrine 
fashion and demonstrate protective effects in other organs or within the muscle fiber 
itself (Pedersen & Febbraio, 2012). While the release of exercise-induced myokines has 
beneficial potential for individuals suffering from muscle atrophy, there are additional 
protective mechanisms and effects of exercise that have been explored. For instance, the 
advantageous effects of exercise on DOX-induced skeletal and cardiac muscle 
dysfunction, oxidative stress, and mitochondrial toxicity have been extensively 
investigated.  
Exercise has influenced the expression of negative regulators of muscle mass in 
skeletal muscle tissue, which is another protective mechanism against muscle wasting. 
Chen, Mou, Yang, Wang, and Zhao (2011), were the first to report that decreased muscle 
wasting observed following exercise training in individuals with diabetes may be related 
to an inhibition of oxidative stress-induced mechanisms. According to Chen et al. (2011) 
oxidative stress was decreased in rats with diabetes following exercise training. This 
reduction in oxidative stress was correlated with a significant decrease in MuRF-1 
expression, which may have prevented the breakdown of both slow and fast MHC. These 
findings were similar to that of Clarke et al. (2007), where MHC expression in C2C12 
myotubes was maintained due to MuRF-1 inhibition following administration of DEX. 
Smuder, Kavazis, Min, and Powers (2011) also investigated the impact of exercise on 
skeletal muscle following DOX administration, but focused specifically on markers of 
autophagy, which is a protein degradation system that can be triggered by oxidative 
stress. Expression of autophagy genes was elevated following DOX treatment, but the 






autophagy activity. Similarly, Marques-Aleixo et al. (2015) utilized two models of long-
term exercise, treadmill endurance training and free-wheel exercise, to investigate the 
impact of DOX on mitochondrial oxidative stress and damage. The use of both exercise 
models resulted in overall improved mitochondrial functioning, and it is possible that this 
was a consequence of prevented oxidative damage and stress in the mitochondria.  
Comparably, exercise has employed a protective effect on several physiological 
components other than oxidative stress-induced mechanisms following DOX 
administration. One such mechanism is that the activity of MRFs in the skeletal muscle 
tissue increases due to exercise (Aguiar, Vechetti-Júnior, et al., 2013). Quinn and Hydock 
(2018) were the first to specifically investigate the effects of short-term endurance 
exercise prior to treatment with DOX on MRF expression in slow- and fast-twitch 
skeletal muscle in rats. No significant effects were observed in EDL muscle, which is 
primarily composed of fast-twitch fibers. However, exercise significantly increased Myf5 
expression in SOL muscle, which is almost exclusively comprised of slow-twitch fibers. 
Enhanced MRF expression in SOL muscle in response to exercise may act as a protective 
mechanism against muscle atrophy and dysfunction by providing the muscle with the 
means to repair damage induced by DOX (Bredahl, Pfannenstiel, Quinn, Hayward, & 
Hydock, 2016). 
Different types of exercise training protocols associated with DOX treatment have 
been investigated to determine which protocol elicits the best protective outcomes on 
skeletal muscle function. Bredahl et al. (2016) compared the differences in resistance and 
endurance exercise protocols in diminishing DOX-induced skeletal muscle dysfunction 






Both the resistance and treadmill training protocols improved certain components of 
skeletal muscle function in the SOL muscle, but neither protocol improved any measure 
of EDL muscle function following DOX treatment. These findings indicate that specific 
protective effects of exercise on muscle dysfunction following DOX treatment may 
depend on the type of exercise performed as well as fiber type of the muscle. For 
example, the resistance protocol prevented maximal twitch force and rate of force 
decline, while the treadmill protocol improved the rate of decline in force production in 
the SOL muscle only. Based on these findings, resistance and treadmill training protocols 
may be utilized in a single therapeutic exercise plan to elicit the most protective effects 
on skeletal muscle function. 
Rather than compare the effectiveness of different types of exercise in protecting 
skeletal muscle tissue from damage and dysfunction, Dickinson et al. (2017) assessed the 
timing of an exercise protocol in relation to DOX treatment in rats. Animals completed a 
treadmill interval training protocol five days per week, starting five days prior to the first 
DOX injection, and maintained this frequency throughout the remaining 40-day study 
duration. Two additional injections with DOX were administered at two- and four-weeks 
following the first injection. Animals in the exercise group exhibited less damage to 
MHC I and MHC IIa fibers in the SOL muscle compared to controls. This finding 
suggested that exercise before and during long-term DOX administration may be used as 
a strategy to lessen the severity of damage to skeletal muscle that is primarily oxidative, 









It is well-known that the DIA muscle acts not only as the primary inspiratory 
muscle, but also as a component of several physiological functions throughout the body 
(Kocjan, Adamek, Gzik-Zroska, Czyżewski, & Rydel, 2017). The DIA is comprised of a 
non-contractile tendon and peripheral muscle that conjoin to form a dome-shaped 
partition between the thoracic and abdominal cavities (Downey, 2011). The location of 
the DIA allows for its involvement in the information exchange and signaling in the body 
(Kocjan et al., 2017). The DIA is a skeletal muscle that is mostly under involuntary 
control, but can be voluntarily controlled when necessary (Kokatnur & Rudrappa, 2019) 
and is comprised of a blend of both slow- and fast-twitch fibers (Quinn & Hydock, 2018). 
Meznaric and Cvetko (2016) found that postmortem human costal DIA, the part of the 
muscle that attaches to the ribs, was comprised of approximately 50% slow-twitch and 
47% fast-twitch fibers on average. Also, the cross-sectional area of muscle fibers in the 
DIA was much smaller in comparison to that of other skeletal muscles, such as the vastus 
lateralis muscle. It was suggested that slow-twitch fibers in the DIA encourage fatigue 
resistance, not only due to their aerobic nature, but also because of the reduced distance 
required for the diffusion of oxygen (McKenzie, 2006). 
One primary role of the DIA is to enlarge the chest cavity during inhalation to 
allow air to enter. The DIA is of great importance for respiration (Zhou et al., 2018), 
seeing as approximately 80% of the work required for respiration is accomplished by the 
DIA (Kocjan et al., 2017). In non-cancer populations, respiratory function assessments 
have displayed variations related to the degree of dyspnea (Bruera, Schmitz, Pither, 






breathing (Campbell, 2017) while at rest or during activities requiring exertion, such as 
exercise. In cancer patients, fatigue is most commonly associated with other physical 
symptoms, such as dyspnea (Stone et al., 1999). It is unclear if there is a common 
mechanism of dyspnea in cancer patients, especially when dyspnea is most intense 
(Travers et al., 2008).  
Another key function of the DIA is to block the space where the distal esophagus 
and proximal stomach join in order to protect against reflux (Downey, 2011). Other roles 
of the DIA include assistance with trunk stabilization, childbirth, swallowing, vomiting, 
defecation, and urination, as well as involvement in lymphatic and cardiac functioning. 
The DIA acts as a lymphatic pump during deep breathing, with nearly two-thirds of all 
lymph nodes in the body positioned directly underneath the DIA (Kocjan et al., 2017). 
Furthermore, DIA functioning is related to the modulation of cardiovascular components 
such as stroke volume and cardiac output, which indicates that cardiac and DIA 
dysfunction are interrelated.  
Weakness and Dysfunction 
Numerous studies have investigated DIA muscle dysfunction induced by 
sustained mechanical ventilation in humans as well as DIA muscle weakness following 
periods of hypoxic stress in murine models. Powers et al. (2011) were the first to identify 
that prevention of mitochondrial ROS production in the DIA, through the use of an 
antioxidant targeted to the mitochondria, protected the DIA from ventilator-induced 
weakness in rats. Based on this observation, Powers et al. (2011) were also the first to 






extended mechanical ventilation and that disruption of this ROS production attenuated 
DIA weakness following ventilation. 
An additional protective mechanism against decline in DIA functioning induced 
by prolonged mechanical ventilation was identified by Zambelli et al. (2016). The 
administration of Angiotensin (1-7) (Ang-(1-7)), a peptide involved in processes of the 
renin-angiotensin system, inhibited atrophy of the DIA muscle in mechanically-ventilated 
rats without improving force generation. Levels of MuRF-1 and atrogin-1 were elevated 
following mechanical ventilation, but rats in the Ang-(1-7) administration group 
exhibited a reduction in expression of both ubiquitin ligases. Based on this observation, it 
was suggested that Ang-(1-7) acted in the DIA by suppressing MuRF-1 and atrogin-1 
expression, which offered an explanation for the prevention of DIA muscle wasting. 
Furthermore, O'Leary, Drummond, Edge, and O'Halloran (2018) demonstrated 
the protective effects of N-acetyl cysteine, an antioxidant, on DIA function following 
eight hours of hypoxic stress. Pretreatment with N-acetyl cysteine inhibited dysfunction 
in the DIA induced by hypoxia, as shown by an increase in specific force generation 
following hypoxia in comparison to the control group. Oxidative stress in the DIA was 
also prevented, as indicated by meaningfully lower concentrations of lipid peroxidation 
byproducts compared to those of hypoxia and control groups. 
While an ample amount of research pertaining to MRFs and proteins that 
negatively regulate muscle mass in EDL and SOL muscles has been conducted, less has 
been explored regarding protein expression and signaling in the DIA muscle of animals 
and humans with chronic conditions. Of the research that has been conducted regarding 






individuals with COPD or critically-ill individuals with respiratory dysfunction. 
Testelmans et al. (2010) investigated the signaling pathways of atrophy and hypertrophy, 
protein expression, and muscle fiber characteristics in the DIA muscle of patients with 
COPD in comparison to patients without COPD, but with other chronic conditions. 
MyoD protein expression and mRNA levels as well as cross-sectional area of slow-
twitch, type I, and fast-twitch, type II, muscle fiber types were significantly decreased in 
individuals with COPD. Conversely, binding activity of the NF-κB pathway, MAFbx 
mRNA concentrations, and myostatin protein expression were drastically increased. 
Moreover, the proportion of type I fibers was significantly higher while the proportion of 
type II fibers was reduced in the DIA muscle of COPD patients compared to controls. 
These findings indicate that the signaling pathways of atrophy and hypertrophy in the 
DIA muscle of COPD patients, specifically the ubiquitin-proteasome and NF-κB 
pathways, are modified in comparison to controls. This alteration in activity, along with 
the shift of DIA muscle fibers to a slower profile, may contribute to DIA dysfunction in 
individuals with COPD and other chronic conditions that affect respiration.  
In a similar model of COPD in rats by Zhou et al. (2018), myostatin expression in 
the DIA muscle was significantly greater in COPD animals than controls, which was 
comparable to the findings of Testelmans et al. (2010). However, Zhou et al. (2018) also 
investigated markers of apoptosis in the DIA of COPD animals and observed an increase 
correlated with myostatin expression. Therefore, myostatin may be involved in the 
promotion of apoptosis in the DIA and contribute to its dysfunction in a variety of 
conditions. Zhou et al. (2018) also noted a significant decrease in DIA mass in COPD 






et al. (2010). Hoojiman et al. (2015) focused on the role of the ubiquitin-proteasome 
pathway in muscle wasting and contractile dysfunction in the DIA of critically ill 
individuals who were mechanically ventilated prior to undergoing lung resections. The 
expression of MuRF-1 doubled and MAFbx tripled in the DIA of critically ill individuals 
in comparison to controls, which signified an increased activation of the ubiquitin-
proteasome pathway. Moreover, both slow- and fast-twitch fibers in the DIA exhibited a 
decrease in cross-sectional area and a decline in contractile force by approximately 50% 
in critically ill patients, which supported the results of Testelmans et al. (2010) regarding 
contractile function and muscle fiber characteristics in the DIA.  
Doxorubicin (DOX)-Induced  
Weakness and Dysfunction 
 
 Several studies pertaining to cancer treatment have focused on the impacts of 
DOX administration in a variety of tissues, but its specific effects on DIA muscle 
function and atrophy have been less investigated. Gilliam, Moylan, Callahan, et al. 
(2011) focused on respiratory function in two murine models of chemotherapy, which 
represented the two methods by which cancer patients receive chemotherapy: intravenous 
(i.v.) and intraperitoneal (i.p.) injection. Both methods of administration led to a 
significant decrease in specific force, which was most severe following i.p. injection. As 
a result of i.p. injection with DOX only, oxidant activity in the cytosol, a marker of 
oxidative stress, was doubled in the DIA muscle of mice. Muscle weakness in the DIA 
resulted from both injection methods, which suggested that this loss of force generation 
may have been a potential mechanism for dyspnea in individuals undergoing DOX 






injection with DOX, which highlighted differences in treatment outcomes between the 
two methods.  
Gilliam, Moylan, Ferreira, and Reid (2011) reported another potential mechanism 
for DIA dysfunction related to an increase in TNFR-1 mRNA levels in mice following 
i.v. injection with DOX. Mice with a genetic deficiency of TNFR-1 did not exhibit DIA 
muscle weakness, as determined by a maintenance of specific force following DOX 
administration. This finding indicated that the signaling pathway of TNF-α and TNFR-1 
regulated DOX-induced DIA weakness is likely a mechanism of DIA dysfunction. The 
observations of Gilliam et al. (2009) pertaining to the protection of the DIA muscle in 
TNFR-1 deficient mice are in agreement with those of Gilliam, Moylan, Ferreira, et al. 
(2011). 
Endurance Exercise 
 Endurance exercise has demonstrated an assortment of impacts on MRF 
expression, muscle function, mitochondrial expression, and antioxidant production in the 
DIA, particularly in cases concerning DOX- and ventilator-induced damage. Quinn and 
Hydock (2018) also investigated the effects of exercise training prior to treatment with 
DOX on MRF expression in the DIA muscle. There were no main effects in the DIA 
muscle from DOX treatment, which supports the concept that DOX treatment influences 
skeletal muscle differentially based on muscle fiber type. This conclusion was in 
agreement with that of Bredahl et al. (2016), where DOX differentially affected EDL and 
SOL muscle. 
The first evidence that an exercise protocol could provide protection against 






treadmill protocol protected the DIA muscle of rats against ventilator-induced oxidative 
damage in the mitochondria. A potential mechanism behind this observed protection was 
investigated by Sollanek et al. (2017), by comparing the set of expressed proteins in the 
DIA muscle of sedentary rats to that of endurance-trained rats. In the mitochondria of the 
DIA, the endurance exercise protocol significantly increased the relative abundance of 
proteins associated with protection of the cytosol in other cell types. While the functions 
of these proteins in the DIA muscle are not fully understood, these observations provided 
evidence that these proteins may be necessary for, or at least encourage, exercise-induced 
protection against muscle wasting due to sedentary behavior.  
These findings regarding exercise-induced protection in the DIA have also been 
applied to research involving DOX treatment. Two weeks of treadmill exercise preserved 
respiratory function, mitochondrial function, and DIA tissue following DOX treatment by 
reducing mitochondrial accumulation of DOX and ROS production according to Morton, 
Mor Huertas, et al. (2019). Moreover, Morton, Smuder, et al. (2019) hypothesized that 
mitochondrial antioxidant enzyme superoxide dismutase (SOD2) needed to be elevated in 
order for exercise to have a protective effect against DIA dysfunction induced by 
mechanical ventilation based on previously reported findings. Upon prevention of the 
exercise-induced increase in diaphragmatic SOD2, exercise-mediated protection from 
DIA atrophy was absent while protection against contractile dysfunction was only 
moderately lost. These observations signify that increased antioxidant, specifically 
SOD2, expression in the DIA is required to fully attain exercise-induced protection 






While endurance exercise is known to increase muscle damage of mdx mice, less 
is understood about the influence of sex on muscle wasting, particularly in the DIA. 
Hermes et al. (2018) compared the effects of exercise on DIA muscle response in male 
and female mdx mice by measuring CK levels, quantifying regenerated DIA muscle 
fibers, and assessing alpha and beta estrogen receptors (ER) in comparison to controls. 
Female mdx mice in the exercise group demonstrated the greatest alpha and beta ER 
expression. Male mdx mice presented the highest quantification of regenerated fibers and 
the exercise group specifically exhibited increased CK levels. Therefore, DIA damage 
and inflammation may have been selectively prevented in mdx mice based on ER 
expression and estrogen presence of the different sexes.  
Conclusion 
At least half of cancer patients worldwide have reported symptoms of fatigue 
associated with their condition (Mohandas et al., 2017). This cancer-associated fatigue 
likely affects patients receiving chemotherapy and radiation therapy to the greatest extent, 
due to their potency, in comparison to individuals receiving other forms of treatment 
(Irvine et al., 1991). DOX is a chemotherapy drug that can be administered intravenously 
or intraperitoneally to treat several types of cancer and affects the body systemically 
rather than locally. While DOX administration may provide anti-cancer benefits, a major 
limitation is that its toxicity impacts organs that are not the intended targets of treatment. 
Furthermore, the total dose of DOX administered is used to predict the severity of the 
toxicity that will be imposed on the patient (Thorn et al., 2011).  
Cardiac and skeletal muscle dysfunction is a common outcome of chemotherapy 






physiological variables, rather than just the accumulation of DOX, may impact proper 
muscle functioning (Hayward et al., 2013). Hydock et al. (2011) reported a dose-
dependent relationship of DOX treatment on cardiac and skeletal muscle dysfunction, 
while Hayward et al. (2013) observed a time-dependent steady decline in muscle function 
one-, three-, and five-days following DOX administration.  
 Oxidative stress occurs when there is an imbalance of the production of ROS and 
the protection of antioxidants. DOX administration increases ROS creation (Carvalho et 
al., 2009), which may consequently weaken antioxidant defenses. Muscle degradation 
mediators and pathways, such as TGF-β and the ubiquitin-proteasome pathway, are 
influenced by ROS presence. Myostatin is a cytokine belonging to the TGF-β 
superfamily of proteins responsible for cell regulation (Ríos et al., 2004). Factors related 
to muscle atrophy, such as denervation and disuse of skeletal muscle tissue, have been 
observed under conditions of increased myostatin expression (Delfino et al., 2013). 
Myostatin also directly regulates the creation of fibrous connective tissue in skeletal 
muscle, an excess of which can cause fibrosis. Moreover, increases in muscle mass and 
strength have been observed under conditions of inhibited myostatin activity (Tobin & 
Celeste, 2005). The ubiquitin-proteasome system is the main regulatory mechanism of 
skeletal muscle protein degradation. Levels of MuRF-1 and MAFbx, two ubiquitin 
ligases, play a role in muscle wasting, as demonstrated by their activation in numerous 
models of muscle atrophy (Foletta et al., 2011). Although the role of ubiquitin ligases in 
skeletal muscle atrophy has been well-established, the involvement of MuRF-1 and 
MAFbx in causing the symptoms specifically experienced by individuals undergoing 






The impact of DOX administration on a variety of tissues has been vastly 
explored, but DOX-induced effects on respiratory function have been less investigated. In 
order for respiration to occur, the DIA must perform more than three-fourths of the total 
amount of work needed (Kocjan et al., 2017). Dyspnea, characterized by uncomfortable 
and/or labored breathing at rest or during exertion, is a common outcome associated with 
chemotherapy treatment, but its exact mechanisms are unknown. A potential mechanism 
of the dyspnea experienced by patients receiving DOX treatment is the decline in specific 
force of the DIA muscle, which was observed in mice following both i.v. and i.p. 
injection with DOX (Gilliam, Moylan, Callahan, et al., 2011).  
Creatine, a substance that is synthesized in the human body and able to be 
obtained from the diet, is involved in supplying energy for use during muscular 
contraction (Fairman et al., 2019). Professional athletes and individuals interested in 
physical fitness have effectively utilized creatine as an ergogenic aid for activities that 
require recurrent bouts of high-intensity exercise. Creatine supplementation has also 
lessened the severity of damage to the body caused by chemotherapy treatment, cachexia, 
and conditions characterized by muscle-wasting, such as muscular dystrophies. 
According to Bredahl and Hydock (2017), ex vivo incubation of the EDL and SOL 
muscles of rats with creatine prior to DOX incubation lessened the severity of DOX-
induced muscle dysfunction. Time-to-fatigue was extended in DOX-treated SOL muscle 
and force decline was attenuated in the EDL muscle following incubation of the muscle 
in a creatine-supplemented organ bath. Similarly, Menezes et al. (2007) reported that 
creatine supplementation demonstrated a protective effect on respiration and DIA muscle 






This study potentially demonstrates the therapeutic benefits of two creatine 
supplementation protocols following DOX administration in lessening the severity of 
DOX-induced increases in negative regulatory protein expression in the DIA muscle at 
one- and three-day time points post-injection. Therefore, this research may provide a 
greater understanding of the mechanisms of negative regulatory protein expression in the 
DIA following DOX administration, and have implications for the possible future 











Animals and Animal Care 
 All procedures and protocols were approved by the Institutional Animal Care and 
Use Committee (IACUC) at the University of Northern Colorado and were performed in 
compliance with the requirements of the Animal Welfare Act. Male Sprague-Dawley rats 
(N =120) were acquired from Envigo (Indianapolis, IN) and were singly housed in cages 
under a 12hr:12hr light:dark cycle in an environmentally managed facility. Animals were 
provided a standard rodent chow from Envigo (Indianapolis, IN) and water upon arrival 
at the facility, which were both available ad libitum. Chow was consistently replaced to 
200 g after 40 g or less was remaining.  
Experimental Design 
 Male Sprague-Dawley rats (ten-week old; N=120) were randomly assigned to one 
of six groups: (1) CON+SAL (control chow, saline, n=20), (2) CON+DOX (control 
chow, doxorubicin, n=20), (3) CrS+SAL (standard creatine diet, saline, n=20), (4) 
CrS+DOX (standard creatine diet, doxorubicin, n=20), (5) CrL+SAL (creatine loading 
diet, saline, n=20), (6) CrL+DOX (creatine loading diet, doxorubicin, n=20). Injections 
with SAL or DOX were delivered at four weeks. Animals were sacrificed at one day 
(One-Day, n=60) or three days (Three-Day, n=60) post-injection. The experimental 































Creatine Monohydrate (Cr) Administration  
Groups randomly assigned to creatine monohydrate supplementation were fed 
rodent chow which was supplemented with a standard creatine dosage (CrS) or a creatine 
loading dosage (CrL). The standard chow provided to the CrS groups was supplemented 
with 2% creatine monohydrate (Sigma-Aldrich®: St. Louis, MO) for four weeks. The 
standard chow provided to the CrL groups was supplemented with 4% Cr for one week, 
followed by 2% Cr for three weeks.  
Doxorubicin (DOX) Treatment 
Animals randomly assigned to DOX treatment groups received an intraperitoneal 
injection of DOX (Teva Pharmaceuticals USA: North Wales, PA) at a dosage of 15 mg 
per 1 kg bodyweight (15mg/kg) while animals in the SAL treatment groups received a 
saline injection (0.9% NaCl) of the same volume. Animals were randomly assigned to 




 Each animal was anesthetized via a single intraperitoneal sodium pentobarbital 
(50 mg/kg) injection in preparation for sacrifice, which occurred at the One-Day (n=60) 
or Three-Day (n=60) time point after SAL or DOX injection. A tail pinch was performed 
when each animal appeared to be visibly anesthetized following the injection. Failure of 
the animal to respond to the tail pinch indicated that the animal was fully anesthetized, 






flash frozen in liquid nitrogen, and stored at a temperature of -80°C in preparation for the 
biochemical analyses of myostatin and MuRF-1 proteins. 
Homogenate Preparation 
 Individual DIA tissue samples were removed from the -80°C freezer and between 
0.5 and 1.0 g of the tissue was placed in a glass tissue homogenizer. For each 1.0 µg 
sample, 10µL of radio-immunoprecipitation assay (RIPA) buffer (Santa Cruz 
Biotechnology: Santa Cruz, CA) was added to the homogenizing tube followed by 10µL 
of protease inhibitor (Sigma-Aldrich®: St. Louis, MO). Each sample was manually 
homogenized using a polytetrafluoroethylene (PTFE) tissue grinder (Cole Parmer: 
Vernon Hills, IL) and cell membranes were further disrupted using a Model 100 Sonic 
Dismembrator (Fisher Scientific: Hampton, NH) through ten, 1-second bursts. The 
contents of the glass tube were transferred to a 2.0 mL Eppendorf tube (Eppendorf: 
Hauppauge, NY) and were centrifuged at room temperature for 10 minutes at 10,000 g. 
After centrifugation, the supernatant was transferred to a new 2.0 mL Eppendorf tube and 
the remaining pellet was discarded.  
 The total protein concentration of each supernatant was quantified using the 
Bradford method (Bradford, 1976; Coomassie Plus Protein Assay Reagent, 
ThermoScientific: Rockford, IL). Spectrophotometry was performed using a Genesys 20 
spectrophotometer (ThermoSpectronic: Rochester, NY) set at 595 nm. This process 
established a standard curve for protein concentration to absorbency, which was 
determined based on wavelength. Five standardized concentrations of BSA (Pre-diluted 
protein assay standards: Bovine serum albumin, ThermoScientific: Rockford, IL; 0.125 






the standard curve of protein concentration to wavelength. The linear equation provided 
from the standard curve, x=(y-b)/m (derived from y=mx+b), was used to predict the 
protein concentration of each 10 µL standard sample analyzed by the spectrophotometer. 
Based on each protein concentration value, a calculated amount of RIPA buffer (Santa 
Cruz Biotechnology: Santa Cruz, CA) was added to 100 µL of each supernatant to 
standardize the protein concentration. An equal amount of Laemmli buffer (Sigma-
Aldrich®: St. Louis, MO) was added in order to decrease the concentration of protein by 
50% and prepare the proteins for gel electrophoresis. Samples were stored at -80°C until 
the Western blot analysis was conducted.  
Western Blotting 
 Western blot analysis was performed to quantify the protein expression of 
myostatin and MuRF-1 in DIA (N=120). Samples were removed from the freezer, 
allowed to completely thaw, heated in boiling water for 2 minutes and chilled for 5 
minutes on ice. Once cooled, 10 µL of each sample was loaded onto Tris-Glycine precast 
gels (4-20% gradient; Invitrogen™, Thermo Fisher Scientific; Waltham, MA) in addition 
to 10 µL of SeeBlueTM protein ladder and Magic MarkTM to track protein separation. The 
running buffer used in electrophoresis was Tris-Glycine SDS Running Buffer 
(ThermoScientific; Waltham, MA). Gels ran at a constant 125 V and 40 mA in an Xcell 
IITM blot module (InvitrogenTM, Thermo Fisher Scientific; Waltham, MA) until the 
tracking dye migrated to the bottom of the gel, which usually occurred within 2 hours.  
 Proteins were then transferred to a polyvinylidene fluoride (PVDF) membrane 
(0.45 µm pore; InvitrolonTM, InvitrogenTM, Thermo Fisher Scientific; Waltham, MA) for 






were incubated in a transfer buffer which consisted of 40 mL of Tris-Glycine Transfer 
Buffer, 760 mL of deionized water, and 200 mL of methanol. Membranes were then 
blocked with 10 mL of Superblocker Solution (Thermo Fisher Scientific; Waltham, MA) 
for 30 minutes and washed in deionized water twice for five minutes. Once blocked, 
membranes were incubated with 10 mL of primary antibody solution for 12 to 18 hours. 
Following incubation with the primary antibody, membranes were washed four times in 
20 mL of Wash Solution (WesternBreezeTM; Thermo Fisher Scientific. Waltham, MA) 
for five minutes and incubated with the suitable secondary antibody (goat anti-mouse, 
1:1000; Santa Cruz Biotechnology; Dallas, TX) for 60 minutes. Lastly, membranes were 
washed four times with 20 mL of Wash Solution (WesternBreezeTM; Thermo Fisher 
Scientific; Waltham, MA) for five minutes and then rinsed with 20 mL of deionized 
water twice for five minutes in preparation for protein band detection and imaging.  
 Enhanced chemiluminescence (ECL) substrate (WesternSure® PREMIUM 
Chemiluminescent Substrate, LI-COR; Lincoln, NE) consisting of luminol and enhancer 
in a 2.0 mL Eppendorf tube (ratio 1:1 mL) was poured onto the testing surface of a 
Western blot scanner (C-Digit, LI-COR: Lincoln, NE). The membrane was incubated 
face-down in the ECL substrate for five minutes prior to the quantification of protein 
expression through the utilization of ImageJ software (NIH; Bethesda, MD).  
The primary antibodies of focus were myostatin (anti-mouse, 1:500 dilution; 
Santa Cruz Biotechnology; Dallas, TX), also known as growth-differentiation factor 8 
(GDF-8), and MuRF-1 (anti-mouse 1:100 dilution; Santa Cruz Biotechnology; Dallas, 
TX). The loading control used for each PVDF membrane was GAPDH (anti-mouse, 






proteins transferred to the PVDF membrane were verified based on a Magic MarkTM 
standard ladder (InvitrogenTM, Thermo Fisher Scientific; Waltham, MA).  
Statistical Analyses 
 Data were analyzed using GraphPad Prism 7 statistical software (GraphPad: La 
Jolla, CA) and are presented as means ± standard error of the mean (means ± SEM). A 
two-factor (diet x drug) analysis of variance (ANOVA) was completed to identify main 
diet effects, main drug effects, and diet x drug interactions at the one-day and three-day 
time points. If significant main effects were observed, Tukey’s post hoc testing was 
performed to determine where differences occurred between groups. Significance was 












 Data are presented as means ± SEM. All animals were fed CON, CrS, or CrL 
diets and were anesthetized at either one day- or three days-post injection with DOX or 
SAL. The DIA of each animal (N=115) was analyzed to identify the potential effect(s) of 
four weeks of Cr supplementation, by means of a standard or loading protocol, in 
combination with DOX or SAL injection on the protein expression of myostatin and 
MuRF-1 at both time points. The DIA tissue samples of five animals were unavailable for 
analysis due to experimenter error during tissue collection or animal death prior to 
sacrifice (N=5). 
General Observations  
The effects of four weeks of CON, CrS, or CrL diets followed by intraperitoneal 
injection with DOX or SAL on percent change (± %) in myostatin and MuRF-1 protein 
expression in the DIA of rats under all conditions and both time points is depicted by 
Tables 1-4. Myostatin and MuRF-1 expression in the DIA of rats under all conditions 









There was no significant drug effect (p = 0.225), diet effect (p = 0.412), or 
interaction (p = 0.770) for myostatin protein expression one day post-injection in the DIA 
(See Figure 3). Myostatin expression was 11.6% greater in the DIA from CON+DOX in 
comparison to CON+SAL one day post-injection. Additionally, myostatin expression was 
1.04% and 10.4% lower in the DIA from CrS+DOX and CrL+DOX respectively, in 
comparison to CON+DOX. Lastly, myostatin expression was 9.47% lower in the DIA 
from CrL+DOX when compared to CrS+DOX (See Table 1).  
 
Table 1 
Percent Change (± %) in Myostatin Expression in One-Day Rat DIA Tissue  
 
 CON+SAL CON+DOX CrS+SAL CrS+DOX CrL+SAL CrL+DOX 
CON+SAL 0.00 +11.6 +11.6 +10.5 -8.14 0.00 
CON+DOX - 0.00 0.00 -1.04 +21.5 -10.4 
CRS+SAL - - 0.00 -1.04 -17.7 -10.4 
CRS+DOX - - - 0.00 +20.3 -9.47 
CRL+SAL - - - - 0.00 +8.86 
CRL+DOX - - - - - 0.00 
Note. DOX, doxorubicin; SAL, saline; CON, control; CrS, Standard creatine diet; CrL, 











Figure 3. Myostatin Expression in the DIA of One-Day Animals. There was not a 
significant diet effect, drug effect, or interaction (N=58). CON, control; CrS, Standard 
creatine diet; CrL, Creatine loading diet; DOX, doxorubicin; SAL, saline. Top bands 













No significant drug effect (p = 0.772), diet effect (p = 0.248), or interaction (p = 
0.137) was observed for MuRF-1 protein expression one day post-injection in the DIA 
(See Figure 4). Although there were no detected interactions between diet and drug or 
main effects, MuRF-1 expression was 51.7% greater in the DIA from CON+DOX when 
compared to CON-SAL one day post-injection. Also, MuRF-1 expression was 14.3% and 
13.2% lower in the DIA from CrS+DOX and CrL+DOX, respectively, in comparison to 
CON+DOX. Finally, MuRF-1 expression was 1.28% greater in the DIA from CrL+DOX 
when compared to CrS+DOX (See Table 2).   
 
Table 2 
Percent Change (± %) in MuRF-1 Expression in One-Day Rat DIA Tissue  
 
 CON+SAL CON+DOX CrS+SAL CrS+DOX CrL+SAL CrL+DOX 
CON+SAL 0.00 +51.7  +43.3  +30.0  +23.3  +31.7  
CON+DOX - 0.00 +5.81  -14.3  +23.0  -13.2  
CRS+SAL - - 0.00 -9.30  -14.0  -8.14  
CRS+DOX - - - 0.00 +5.41  +1.28  
CRL+SAL - - - - 0.00 +6.76  
CRL+DOX - - - - - 0.00 
Note. DOX, doxorubicin; SAL, saline; CON, control; CrS, Standard creatine diet; CrL, 















Figure 4. MuRF-1 Expression in the DIA of One-Day Animals. There was not a 
significant diet effect, drug effect, or interaction (N=58). CON, control; CrS, Standard 
creatine diet; CrL, Creatine loading diet; DOX, doxorubicin; SAL, saline. Top bands 
represent MuRF-1. Bottom bands represent GAPDH as the loading control.








There was no significant drug effect (p = 0.710), diet effect (p = 0.935), or 
interaction (p = 0.566) for myostatin protein expression three days post-injection in the 
DIA (See Figure 5). While there were no detected main effects or interactions between 
variables, myostatin expression was 15.0% greater in the DIA from CON+DOX when 
compared to CON+SAL three days post-injection. Moreover, myostatin expression was 
11.3% and 10.4% lower in the DIA from CrS+DOX and CrL+DOX, respectively, in 
comparison to CON+DOX. Lastly, myostatin expression was 0.98% greater in the DIA 
from CrL+DOX when compared to CrS+DOX (See Table 3). 
 
Table 3 
Percent Change (± %) in Myostatin Expression in Three-Day Rat DIA Tissue  
 
 CON+SAL CON+DOX CS+SAL CrS+DOX CrL+SAL CrL+DOX 
CON+SAL 0.00 +15.0  +25.0  +2.00  -9.00  +3.00  
CON+DOX - 0.00 -8.00  -11.3  +26.4  -10.4  
CrS+SAL - - 0.00 -18.4  -27.2  -17.6  
CrS+DOX - - - 0.00 +12.1  +0.98  
CrL+SAL - - - - 0.00 +13.2  
CrL+DOX - - - - - 0.00 
Note. DOX, doxorubicin; SAL, saline; CON, control; CrS, Standard creatine diet; CrL, 











Figure 5. Myostatin Expression in the DIA of Three-Day Animals. There was not a 
significant diet effect, drug effect, or interaction (N=57). CON, control; CrS, Standard 
creatine diet; CrL, Creatine loading diet; DOX, doxorubicin; SAL, saline. Top bands 
represent myostatin. Bottom bands represent GAPDH as the loading control. 









No significant drug effect (p = 0.826), diet effect (p = 0.931), or interaction (p = 
0.941) was observed for MuRF-1 protein expression three days post-injection in the DIA 
(See Figure 6). Although there were no detected main effects between variables or 
interactions between diet and drug, MuRF-1 expression was 8.53% greater in the DIA 
from CON+DOX in comparison to CON+SAL three days post-injection. Furthermore, 
MuRF-1 expression was 6.43% and 14.3% lower in the DIA from CrS+DOX and 
CrL+DOX, respectively, in comparison to CON+DOX. Finally, MuRF-1 expression was 
8.40% lower in the DIA from CrL+DOX when compared to CrS+DOX (See Table 4). 
 
Table 4 
Percent Change (± %) in MuRF-1 Expression in Three-Day Rat DIA Tissue  
 
 CON+SAL CON+DOX CrS+SAL CrS+DOX CrL+SAL CrL+DOX 
CON+SAL 0 +8.53  +4.65  +1.55  -5.43  -6.98  
CON+DOX - 0 +3.70  -6.43  +14.8  -14.3  
CRS+SAL - - 0 -2.96  -9.63  -11.1  
CRS+DOX - - - 0 +7.38  -8.40  
CRL+SAL - - - - 0 -1.64  
CRL+DOX - - - - - 0 
Note. DOX, doxorubicin; SAL, saline; CON, control; CrS, Standard creatine diet; CrL, 













Figure 6. MuRF-1 Expression in the DIA of Three-Day Animals. There was not a 
significant diet effect, drug effect, or interaction (N=57). CON, control; CrS, Standard 
creatine diet; CrL, Creatine loading diet; DOX, doxorubicin; SAL, saline. Top bands 
represent MuRF-1. Bottom bands represent GAPDH as the loading control.
CON+SAL CON+DOX 
 







 It was hypothesized that (1) DOX (15 mg/kg) administration would increase 
myostatin and MuRF-1 protein expression in the DIA tissue in comparison to SAL (0.9% 
NaCl), (2) Cr supplementation would attenuate the effects of DOX on myostatin and 
MuRF-1 expression at both time points, and (3) the creatine monohydrate loading (CrL) 
protocol would attenuate the effects of DOX to the greatest extent at both time points. 
There were no significant main diet effects, drug effects, or any diet x drug interactions at 
either time point among protein expression of myostatin and MuRF-1 in the DIA tissue as 












It is well-known that DOX administration leads to a decline in MRF expression in 
skeletal muscle, which disrupts muscle growth, causes atrophy, and potentially allows for 
increased activity of negative regulators of muscle mass, such as myostatin and MuRF-1. 
Skeletal muscle wasting and fatigue are common side effects of DOX administration, but 
increased skeletal muscle mass and strength, as well as decreased muscle atrophy, have 
been observed under conditions of inhibited myostatin and MuRF-1 activity (Tobin & 
Celeste, 2005; Rom & Reznick, 2016). Additionally, function and contractile strength of 
the DIA muscle are negatively impacted by DOX administration, which may be related to 
dyspnea experienced by patients undergoing chemotherapy treatment (Gilliam, Moylan, 
Callahan, et al., 2011). Therefore, it was hypothesized that DOX administration would 
lead to an increased expression of myostatin and MuRF-1 protein in the DIA.  
Creatine is a widely used dietary supplement that has been shown to improve 
short-term, high-intensity athletic performance and offer potential therapeutic benefits to 
individuals with muscle wasting diseases and patients with chemotherapy-induced 
muscle dysfunction, weakness, and wasting. The most effective means of creatine 
supplementation is dietary (Riesberg et al., 2016) and involves a short-term loading 
period followed by a maintenance period (Kreider et al., 2017). However, stores of 
creatine can also be increased in skeletal muscle by standard supplementation protocols 






loading, CrL, or standard, CrS, protocols would lessen the severity of DOX-induced 
changes in protein expression in comparison to control, CON. It was also hypothesized 
that the CrL protocol would elicit the most protective effects against DOX-induced 
alterations in myostatin and MuRF-1 protein expression in the DIA.  
This was the first known study to analyze myostatin and MuRF-1 protein 
expression in the DIA of rats supplemented with Cr and later treated with a single 
intraperitoneal injection of DOX. The main focus of this research was to compare the 
effects of two Cr supplementation protocols, CrS and CrL, on protein expression in the 
DIA of rats sacrificed at one- and three-day time points following DOX administration. 
There were no statistically significant main effects on protein expression in the DIA as a 
result of Cr supplementation, DOX treatment, nor was there a diet x drug interaction.  
While there were no significant diet effects, drug effects, or an interaction of diet 
and drug, potential trends demonstrating the potentially negative outcomes of DOX 
treatment and beneficial effects of Cr supplementation on DIA protein composition were 
observed. There was a potential trend in the CON+DOX group toward increased 
myostatin and MuRF-1 expression in the DIA in comparison to CON+SAL groups at the 
one-day time point by 11.6% (See Table 1) and 51.7% (See Table 2), respectively. 
Likewise, myostatin and MuRF-1 expression in the CON+DOX group was increased by 
15.0% (See Table 3) and 8.53% (See Table 4), respectively, in comparison to CON+SAL 
groups at the three-day time point.  
Based on the hypothesis that myostatin and MuRF-1 protein expression in skeletal 
muscle is associated with DOX presence in the tissue, the findings of Hayward et al. 






greatest one day post-injection. Hayward et al. (2013) did not implement a creatine 
supplementation protocol to be paired with DOX administration and reported that DOX 
accumulation in the EDL and SOL muscles was greatest one day after DOX injection. 
This finding seems to be in disagreement with the protein expression results of the 
current study, where myostatin expression was greater in the CON+DOX groups at the 
three-day time point in comparison to the one-day time point (See Figures 3 and 5). The 
expression of MuRF-1 was also higher in the CON+DOX groups at the three-day time 
point in comparison to the one-day time point (See Figures 4 and 6). Furthermore, the 
findings of Yamada et al. (1995) pertaining to DOX accumulation in the DIA are similar 
to those of Hayward et al. (2013) regarding DOX accumulation in the EDL and SOL 
muscles of rats. According to Yamada et al. (1995), DOX concentration in the DIA was 
highest six hours post-injection with DOX and declined by over 95% within one week. 
The observations of Hayward et al. (2013) and Yamada et al. (1995) do not appear to 
support the findings of the current study, where myostatin and MuRF-1 expression was 
greater at the three-day time point in comparison to the one-day time point. Based on 
these observations, DOX accumulation may differentially affect skeletal muscles, 
perhaps due to variations in the composition of fiber types. Additionally, these findings 
indicate that the initiation of mechanisms that contribute to myostatin and MuRF-1 
protein expression in the DIA may occur more than one-day post-injection with DOX or 
other mechanisms may influence myostatin and MuRF-1 expression. 
Supplementation with both Cr protocols in DOX groups potentially trended 
toward decreasing myostatin and MuRF-1 expression in the DIA at both time points 






groups was decreased by 1.10% and 11.6%, respectively, in comparison to the 
CON+DOX group at the one-day time point (See Table 1). MuRF-1 expression in 
CrS+DOX and CrL+DOX groups was decreased by 21.7% and 20.0%, respectively, in 
comparison to the CON+DOX group at the one-day time point (See Table 2). Similarly, 
myostatin expression in CrS+DOX and CrL+DOX groups was decreased by 13.0% and 
12.0%, respectively, in comparison to the CON+DOX group at the three-day time point 
(See Table 3). The expression of MuRF-1 in CrS+DOX and CrL+DOX groups was 
decreased by 6.98% and 15.5%, respectively, in comparison to the CON+DOX group at 
the three-day time point (See Table 4). 
Neither protocol was shown to be superior in decreasing the expression of both 
proteins at the one- and three-day time points, even though there was a potential trend 
toward decreasing myostatin and MuRF-1 protein expression in the DIA after both Cr 
supplementation protocols when compared to CON-SAL. For instance, myostatin 
expression was 10.5% lower and 1.00% higher in the CrL-DOX group at the one- and 
three-day time points, respectively, in comparison to the CrS-DOX group (See Tables 1 
and 3). Moreover, MuRF-1 expression was 1.70% higher and 8.53% lower in the CrL-
DOX group at the one- and three-day time points, respectively, in comparison to the CrS-
DOX group (See Tables 2 and 4). 
While a majority of the results of the present study were unanticipated, some were 
potentially explained by the outcomes of past research pertaining to regulatory protein 
expression in the DIA. The observed potential trend in decreased myostatin and MuRF-1 
protein expression supports the conclusions of Cannata et al. (2010), where increased 






spiny rats due to maternal creatine supplementation. Additionally, creatine 
supplementation may have had a protective effect against DIA muscle atrophy even 
though markers of muscle atrophy were not specifically measured in the current study. 
For example, Testelmans et al. (2010) noted that atrophy was present even in cases of 
lower than average diaphragmatic myostatin mRNA levels. Based on this finding, 
myostatin may function to prevent muscle growth more so than to induce muscle wasting. 
Rather than solely focus on protein expression in the DIA, markers of muscle atrophy, 
such as muscle fiber cross-sectional area, should also be investigated in the future. 
Overall, the hypotheses were not supported with statistically significant data. 
However, a trend toward an increase in myostatin and MuRF-1 expression in the DIA 
was observed at both time points in the CON-DOX group when compared to the CON-
SAL group. Neither Cr supplementation protocol led to a statistically significant 
attenuation of DOX effects on myostatin and MuRF-1 expression at either time point. 
Further investigation is required to determine if creatine supplementation is directly 
related to myostatin and MuRF-1 expression in the DIA or indirectly associated with 
other mediators and pathways related to protein degradation and synthesis. 
Limitations  
 One of the primary limitations of this research was that the sacrifice time of rats 
in the one-day and three-day groups was not exactly 24 hours and 72 hours post-
injection, respectively, with DOX. Since the time of sacrifice following DOX 
administration may have varied slightly between animals in the same groups, protein 
expression may have been impacted. Additionally, a Western blot technique was utilized 






been ideal. The accuracy of protein quantification throughout the DIA tissue samples 
may have been improved through the utilization of immunohistostaining methods. Lastly, 
the sample sizes utilized for each group were unequal due to experimenter error during 
DIA tissue removal and storage, as well as animal death from DOX-induced toxicity 
prior to sacrifice.  
Future Directions 
Future research should focus on the expression of proteins in the DIA other than 
myostatin and MuRF-1, as these findings suggest that other regulatory proteins and 
mechanisms may contribute to the respiratory function decline and dyspnea observed in 
individuals being treated with DOX. It may also be of interest to add an exercise 
component to the study design, since both endurance and resistance training prior to 
DOX administration in rats have been associated with an increased activity of 
mechanisms in the muscle that protect against skeletal muscle wasting and function 
decline (Bredahl et al., 2016). Furthermore, Marques-Aleixo et al. (2015) observed a 
potential reduction in oxidative stress and damage in the heart mitochondria of rats 
following short-term DOX treatment and the implementation of two exercise training 
protocols. 
In order to obtain a greater understanding of mechanisms contributing to the 
decline of respiratory function in different sexes, the effects of Cr supplementation in 
both male and female rats should be investigated in DOX-treated animals. This may be 
relevant to human populations with degenerative muscle diseases or individuals 
undergoing chemotherapy treatment, because Hermes et al. (2018) suggested that 






an exercise protocol. Furthermore, future researchers should measure the contractile force 
of DIA muscle from each group in order to investigate the potential relationship between 
DIA muscle dysfunction and the expression of specific proteins in the DIA. Contractile 
force of the DIA muscle should be measured using a force transducer in an experimental 
protocol, similar to the methods utilized by O’Leary et al. (2018), because past research 
has concluded that similar Cr supplementation and DOX administration protocols have 
impacted skeletal muscle functioning. For example, Bredahl and Hydock (2017) reported 
that isolated SOL and EDL muscles treated with Cr prior to incubation with DOX were 
protected from the fatigue typically induced by DOX. However, DIA muscle fatigue has 
not specifically been investigated under the same experimental conditions created by 
Bredahl and Hydock (2017), which may be of future interest.   
Conclusion 
The current study analyzed the effects of Cr treatment paired with DOX 
administration on myostatin and MuRF-1 protein expression in the DIA of rats at two 
time points following DOX injection. There were no significant diet effects, drug effects, 
or interactions at either timepoint among protein expression in the DIA (p > 0.05). 
However, there were trends toward decreased myostatin and MuRF-1 expression in the 
DIA. It is hoped that the use of Cr supplementation in individuals undergoing DOX 
treatment can attenuate the negative outcomes on respiratory and DIA functioning 
experienced by cancer patients, especially when paired with an appropriate exercise 
training protocol. Future research should highlight the expression of other regulatory 
proteins in the DIA, effects of DOX in the DIA at hourly time points following treatment, 






supplementation and DOX administration, and the influence of sex on muscular damage 
in the DIA, in order to identify mechanisms contributing to respiratory and DIA 
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